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A ﬂare, spurting out from Mars – 
Bright green, drawing a green mist behind it – 
a beautiful, but somehow disturbing sight. 
Ogilvy, the astronomer, assured me we were in no danger. 
He was convinced there could be no living thing on that 
remote, forbidding planet.
“The chances of anything coming from Mars are a million 
to one,” he said.
“The chances of anything coming from Mars are a million 
to one - but still they come!”
Jeff Wayne
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1.1. Epilepsy
 Epilepsy is deﬁned as a condition in which the patient is prone to experience 
recurrent epileptic seizures (Shorvon, 2000). Epileptic seizures result from excessive 
discharge in a population of hyperexcitable neurons in the brain. The clinical expression 
of a seizure depends on its site of origin, time course and discharge propagation. 
Seizures can be classiﬁed clinically into two categories: partial and generalised. 
 Partial seizures originate in a small group of neurons that constitute a seizure 
focus. Thus, the symptomatology depends on the location of the focus within the brain. 
These partial seizures can be either simple partial (no alteration of consciousness) or 
complex partial (with alteration of consciousness).  
 Generalised seizures begin without any preceding symptoms of a focal 
seizure and involve both hemispheres from the onset. These types of seizures are 
usually bilateral in their initial manifestations and as a rule are associated with an early 
impairment or loss of consciousness. They can be further divided into convulsive or 
nonconvulsive types. The convulsive generalised seizures can consist only of motor 
movements (myoclonic, clonic, or tonic) or a sudden loss of motor tone (atonic). 
However, the most common (convulsive) generalised seizure is the tonic-clonic (grand 
mal) seizure. The prototypic nonconvulsive generalised seizure is the typical absence 
(petit mal) seizure found in children.
1.1.1. Absence epilepsy
 Absence epilepsy, a non-convulsive epilepsy of multifactorial origin, is 
characterised by a sudden interruption of both physical and mental activity, without 
major loss of postural tone, coupled bilateral synchronous spike and wave discharges 
(SWDs; the term SWD is used throughout this thesis to indicate one continuous 
sequence of spike and wave discharge activity during an absence epileptic seizure) on 
the electroencephalogram (EEG) (Panayiotopoulos, 1997) (see ﬁgure1). No structural 
lesion of any kind has ever been identiﬁed as the substrate of absence epilepsy 
(Berkovic et al., 1987; Niedermeyer, 1996), and the cause is increasingly regarded 
as genetic (McNamara, 1994; Gauguier et al., 2004). However, environmental 
inﬂuences were also shown to affect SWD activity (Schridde, 2005). Because absence 
epilepsy mainly affects children and adolescents, and has moderate consequences, 
studies of the pathophysiological mechanisms cannot be conducted in humans 
for ethical reasons. Therefore, much of the recent information available about the 
pathophysiology of absence epilepsy is derived from studies in animal models 
(Marescaux et al., 1992b; Coenen and Van Luijtelaar, 2003). 
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 1.1.1.1. The WAG/Rij rat model of absence epilepsy
 The WAG/Rij is an inbred strain in which brother-sister mating has been 
conducted for more than 130 generations. Characteristics in the behaviour of WAG/Rij 
rats have been studied extensively and are quite similar to those of outbred Wistar rats 
(Coenen and Van Luijtelaar, 2003). However, all adult WAG/Rij rats (see ﬁgure 2) show 
SWDs in their EEG together with mild clinical manifestations, such as twitching of the 
vibrissae, accelerated breathing, head tilting, and otherwise the animals are immobile 
(Van Luijtelaar and Coenen, 1986; Coenen and Van Luijtelaar, 2003).
These rats have about 16-20 SWDs per hour, with an average duration of about 5 sec 
ranging from 1-30 sec (Van Luijtelaar and Coenen, 1986; Coenen and Van Luijtelaar, 
2003). These SWDs in the cortical EEG of adult WAG/Rij rats have a SWD peak 
frequency of 7-10 Hz (Drinkenburg et al., 1993), which is considerably higher than in 
humans were the SWDs have a typical peak frequency of 3 Hz (see ﬁgure 1; Doose, 
1989). The peak frequency in WAG/Rij rats was found to decrease monotonously from 
about 10 Hz at the beginning of the SWD to about 8 Hz at the end (Coenen and Van 
Luijtelaar, 2003).
Figure 1.  A girl during normal wakefulness (left) and an absence seizure (right) with the corresponding EEG.   
 Adapted from Doose (1989).
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 The states of vigilance highly inﬂuence the occurrence of SWDs. Indeed, in 
more than 80% of the cases, SWDs appear during passive wakefulness or during 
light slow-wave sleep (Drinkenburg et al., 1991); this closely corresponds to human 
absence epilepsy. Furthermore, the effects of anti-epileptic drugs in WAG/Rij rats are 
similar to effects in human absence epilepsy. Indeed, anti-absence drugs cause a 
decrease in the SWD activity, whereas the anticonvulsive drugs (often GABA agonists) 
trigger a substantial increase (Peeters et al., 1988; Coenen et al., 1995; Avanzini and 
Franceschetti, 2003; Coenen and Van Luijtelaar, 2003).
1.1.2. Mechanisms underlying absence epilepsy
 The occurrence of absence seizures is known to involve a close interaction 
between thalamic and cortical structures (see ﬁgure 3) (Crunelli and Leresche, 2002; 
Timofeev and Steriade, 2004), although the relative roles played by the different parts 
of this circuitry are still a matter of debate. As the thalamus and cortex were shown to 
be important, the neurotransmitters in this circuitry are involved. Thalamocortical and 
corticothalamic projections are mainly glutamatergic, whereas several intracortical 
and intrathalamic inhibitory γ-aminobutyric acid (GABA)-ergic projections have been 
described (Blumenfeld, 2003).
Figure 2. A WAG/Rij rat during an absence seizure with the corresponding EEG.
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 The generation of SWDs may be due to dysfunctions at the level of the 
thalamus. In particular the GABAergic projections from the reticular thalamic nucleus 
(Rtn) on thalamic relay nuclei, which contain thalamocortical cells (TC cells), might be 
implicated (Danober et al., 1998). However, recent experimental ﬁndings indicated the 
perioral region of the somatosensory cortex as the initiation site of the SWDs (Meeren 
et al., 2002). Furthermore, fronto-parietal slices of brains of WAG/Rij rats were shown 
to have an intracortical hyperexcitability and a reduction in the efﬁciency of GABAergic 
inhibition (Luhmann et al., 1995). 
 The cellular mechanisms underlying the SWDs involve complex intrinsic ﬁring 
properties of thalamic and cortical neurons, which interact through multiple types 
of synaptic receptors. Unfortunately, due to the complexity of these interactions, 
the detailed sequence of events underlying the SWDs in the EEG remains unclear 
(Niedermeyer, 1996). Nevertheless, it has been shown that both cortical and thalamic 
neurons are necessary to generate SWDs and that GABAergic neurotransmission is 
actively involved (Gloor et al., 1977; Hosford et al., 1992; Snead, 1992; von Krosigk et 
al., 1993; Puigcerver et al., 1996; Steriade and Contreras, 1998; Meeren et al., 2002).
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Figure 3. A schematic representation of the thalamocortical system. Adapted from Depaulis and van Luijtelaar   
 (2005). 
1.2. GABA
1.2.1 The GABA metabolism
 In general, the net activity of the central nervous system (CNS) is a result 
of the balance between the excitatory and the inhibitory neurotransmission. The 
excitatory neurotransmission is mainly mediated by the amino-acid glutamate, 
whereas the inhibitory neurotransmission is mainly mediated by the amino-acid γ-
aminobutyric acid (GABA). Interestingly, GABA is formed in GABAergic neurons from 
glutamate by the enzyme glutamic acid decarboxylase (GAD) (Treiman, 2001). GABA 
is stored in presynaptic vesicles and is released during an action potential. After its 
release into the synaptic cleft, GABA binds to the GABA receptors on the pre- and 
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postsynaptic membrane (Macdonald and Olsen, 1994).
 The presence of GABA in the synaptic cleft can be regulated by re-uptake 
of GABA into GABAergic nerve-terminals as well as by the metabolic transformation 
into succinic acid semialdehyde (SSA) by the enzyme GABA transaminase (GABA-T) 
(Krogsgaard Larsen, 1988; Rang and Urban, 1995).
 
1.2.1.1. Pharmacological manipulation of the GABA metabolism
 Since GABA itself is unable to pass the blood-brain barrier (Burns et al., 
1981), systemic injection of GABA has no effect on GABA concentrations in the brain. 
Therefore, in order to experimentally manipulate GABA concentrations in the brain, 
compounds that interfere with the normal re-uptake and metabolic inactivation of 
GABA can be used (see ﬁgure 4).  
 One of such compounds is the irreversible GABA-T inhibitor vigabatrin (γ-
vinyl-GABA) (Hammond and Wilder, 1985). Vigabatrin binds irreversibly to the active 
site on the enzyme, and enzymatic activity therefore only recovers when new enzyme 
is synthesized. Indeed, after a single systemic administration of vigabatrin, GABA-T 
activity decreases, and GABA levels increase throughout the brain (Hammond and 
Wilder, 1985; Valdizán et al., 1999; Tong et al., 2000). GABA-T levels decrease rapidly, 
reaching a minimum level within 3 to 4 hours after vigabatrin administration (Hammond 
and Wilder, 1985). Whole brain GABA concentrations are maximally increased 4 
hours after injection; this level is maintained for 24 hours and then declines slowly 
(Hammond and Wilder, 1985; Valdizán et al., 1999).
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Figure 4. The possible sites of interaction of drugs in the GABAergic metabolism. Adapted from Upton (1994).
1.2.2. The GABA receptors
 The GABAergic neurotransmission system contains three receptor types; 
the GABAA, GABAB and GABAC receptors. The GABAC receptors are located in the 
retina (Pirker et al., 2000), in contrast to the GABAA and GABAB receptors, which are 
located throughout the CNS. The GABAA and GABAC receptors are members of the 
ligand-gated ion channel family. Upon binding to the GABAA receptor, GABA facilitates 
the opening of the chloride (Cl-) channel, resulting in hyperpolarisation of the neuron 
(Lan and Gee, 1994; Olsen and Sapp, 1995). The GABAB receptor is a metabotropic, 
guanine nucleotide (G protein)-coupled receptor. Upon binding to this receptor, GABA 
activates a second messenger cascade that is connected to a potassium (K+) and a 
calcium (Ca2+) channel (Bowery and Enna, 2000).
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1.2.2.1. The GABAA receptor
 The GABAA receptor is by far the most prevalent of the GABA receptors in the 
mammalian CNS. The GABAA receptor has a heteropentameric structure, consisting of 
ﬁve homologous membrane-spanning subunits that form the Cl- channel (see ﬁgure 5). 
At least eight GABAA receptor subunit types can be distinguished: α, β, γ, δ, θ, ε, π and 
ρ. Several isoforms of these subunits have been identiﬁed: α1-α6, β1-β4, γ1-γ3, and ρ1-ρ3 
(Barnard et al., 1998; Rudolph et al., 2001; Whiting et al., 1999).The GABAA receptors 
can be formed from these different subunits. Depending on this subunit composition 
GABAA receptors exhibit distinct pharmacological properties (Sieghart, 1995). Due to 
regional differences in subunit gene expression, there is a regional variation in different 
subtypes of GABAA receptors, giving rise to possible regional effects of different 
compounds (Pirker et al., 2000).
 The GABAA receptors contain several binding sites; an agonist site (binding 
GABA, muscimol), a picrotoxin site, sites for allosteric modulators such as: 
benzodiazepines, neuroactive steroids, barbiturates, ethanol, and sites for other 
compounds such as stereoselective inhalation anaesthetics, furosemide, Zn2+ ions, 
divalent cations and La3+ ions (Johnston, 1996). Binding of GABAA agonists results 
in the opening of the Cl- channel, Cl- inﬂux and hyperpolarisation, eventually leading 
to fast inhibitory postsynaptic potentials (IPSPs) which decrease the ﬁring rate of the 
postsynaptic neuron. Furthermore, the allosteric modulators of the GABAA receptor 
enhance the opening frequency and/or the opening duration of the Cl- channel, when 
the channel is activated as a result of the binding of a GABAA agonist (reviewed in 
Korpi et al., 2002). Interestingly, all the binding sites are allosterically coupled, resulting 
in a network of interactions that ultimately regulate the permeability of the Cl- channel. 
Obviously, the GABAergic neurotransmission can be inﬂuenced by pharmacological 
manipulation of the GABAA receptors. Furthermore, due to the network of allosterically 
coupled subunits, this receptor type might be a very interesting target for complex 
pharmacological manipulations such as polytherapy.
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Figure 5. Schematic representation of the GABAA receptor consisting of ﬁve homologous membrane-spanning   
 subunits that form the Cl- channel. Adapted from Cooper et al. (1996).
1.2.2.1.1. Pharmacological manipulation of the GABAA receptor
 The classical benzodiazepines, such as diazepam, have comparable binding 
afﬁnities for GABAA receptors containing a γ2, a β and an α1, α2, α3 or α5 subunit 
(Sieghart, 1995), whereas they do not interact with an α4 or α6 subunit. Furthermore, 
GABAA receptors which lack the γ2 subunit are insensitive to benzodiazepines 
(Gunther et al., 1995). Interestingly, in the thalamus, benzodiazepine binding GABAA 
receptors are speciﬁcally located in the Rtn (Pirker et al., 2000).
 In contrast to the benzodiazepines, the γ subunit is not required for the 
GABA modulatory action of neuroactive steroids. Furthermore, low concentrations of 
neuroactive steroids are more effective at α1 and α3 containing receptors compared 
with α2, α4, α5 and α6 containing receptors (Belelli et al., 2002). Nevertheless, a GABAA 
receptor containing a δ, α4 and a β3 subunit is highly neuroactive steroid sensitive 
(Belelli et al., 2002). In the thalamus, such α4β3δ GABAA receptors are not present in 
the Rtn, whereas they are located in other thalamic nuclei (Pirker et al., 2000).
 Systemic stimulation of GABAA receptors via administration of GABAA agonists, 
GABA-T inhibitors, or GABA reuptake inhibitors causes an exacerbation of the SWDs 
in pharmacological and genetic animal models of absence epilepsy (Peeters et al., 
1988; Peeters et al., 1989; Coenen et al., 1995; Marescaux et al., 1992b; Coenen and 
Van Luijtelaar, 2003). Because benzodiazepines augment GABAA receptor mediated 
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neurotransmission, these compounds would be predicted to exacerbate absence 
epileptic SWDs in a similar fashion. Interestingly, the benzodiazepines have been 
shown to have both experimental and clinical therapeutic efﬁcacy in the treatment 
of absence epilepsy (Faingold and Browning, 1987; Marescaux et al., 1992b; 
Coenen and Van Luijtelaar, 2003). Most likely, the reason for this dichotomy is that 
benzodiazepines enhance GABAA receptor mediated inhibition within the Rtn, resulting 
in a decreased inhibition by the Rtn of the thalamic relay nuclei (Huguenard and 
Prince, 1994; Wong and Snead, 2001).
 Interestingly, in vitro it was shown that GABA and diazepam (van Rijn, 
unpublished observation), and GABA and neuroactive steroids (van Rijn et al., 1999; 
van Rijn and Willems-van Bree, 2004) have a synergistic polytherapy interaction. In 
this thesis it is investigated whether these in vitro observed polytherapy interactions 
can be translated to the in vivo situation.
1.2.2.2. The GABAB receptor
 Also, the GABAB receptor is not a single protein, it consists of two distinct 
subunits, the GABAB(1) and the GABAB(2) type (see ﬁgure 6), neither of which is 
functional on its own (Bettler et al., 2004; Couve et al., 2004). Moreover, it appears that 
most, possibly all, GABAB receptors are of the heteromeric GABAB(1,2) type (Bettler et 
al., 2004). 
 All, GABAB agonists and competitive antagonists bind to the extracellular 
domain of the GABAB(1) subunit. Furthermore, there is an allosteric Ca
2+ binding site at 
the GABAB(1) receptor (Bettler et al., 2004). Most people will agree that the GABAB(2) 
subunit does not bind agonists or antagonists and does not function when expressed 
alone. However, the GABAB(2) subunit also contains the large extracellular domain that 
binds ligands in the GABAB(1) subunit. Therefore, it is conceivable that the recently 
developed allosteric modulators bind speciﬁcally to the GABAB(2) subunit (Bettler et al., 
2004). 
 Binding of GABAB agonists results in the activation of G proteins, which causes 
a decrease in Ca2+ and an increase in K+ membrane conductance (Bowery and Enna, 
2000). Due to this indirect mechanism, GABAB mediated IPSPs are delayed in their 
onset and have a slow time course (Nicoll, 2004).
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1.2.2.2.1. Pharmacological manipulation of the GABAB receptor
 Although several GABAB receptor agonists have been synthesized and tested, 
the number of potent and selective compounds is limited (Froestl et al., 1995). Indeed, 
baclofen, which was introduced some 30 years ago, remains one of the most potent 
and selective agents for stimulation of the GABAB receptor.
 In animal models of absence epilepsy, GABAB agonists exacerbate SWD 
activity whereas antagonists block it (Vergnes et al., 1984; Marescaux et al., 1992a; 
Coenen and van Luijtelaar, 2003). Interestingly, the thalamic nuclei are among the 
brain regions having the highest density of GABAB binding sites (Bowery et al., 1987; 
Chu et al., 1990). In the thalamus, GABAB receptor activation produces a prolonged 
postsynaptic hyperpolarisation, which in turn initiates Ca2+ spiking activity in the TC 
cells. This effect is believed to be (partly) responsible for the spike and wave activity 
characteristic of absence seizures (Bowery and Enna, 2000). Moreover, GABAB 
neurotransmission in the somatosensory cortex as well as in the thalamus is believed 
to play a role in the control and generalisation, as well as possible initiation of the 
SWDs (Manning et al., 2004). 
 Nevertheless, there seems to be no exclusive contribution of GABAB receptors 
to spontaneous SWDs in absence epileptic rats (Staak and Pape, 2001), more likely 
the balance between GABAA and GABAB neurotransmission is important for the 
occurrence and control of the SWDs (Destexhe, 1999; Destexhe and Sejnowski, 
2003).
Figure 6. Schematic representation of the GABAB receptor, showing the dimeric nature of the structure. The α, β  
 and γ, G protein subunits; K+ channel; Ca2+ channel and adenylate cyclase (AC) are indicated. (Bowery 
 and Enna, 2000; adapted from Bettler et al., 1998)
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1.3. Measured variables
1.3.1. The electroencephalogram (EEG)
 The electrical activity shown in the EEG reﬂects the summated activity of many 
neurons. The surface EEG shows typical patterns of activity that can be correlated with 
various stages of sleep and wakefulness, and with some pathophysiological processes 
such as absence epileptic seizures. 
1.3.1.1. The spike and wave discharges (SWDs)
 Figure 7 shows a typical SWD of a drug free WAG/Rij rat. The properties of the 
SWDs might reﬂect the properties of the underlying mechanisms. These properties 
might be pharmacologically manipulated. Then changes in the incidence of the SWDs 
might give an insight into the mechanisms involved in the generation of the SWDs, 
whereas changes in the average duration of the SWDs might give an insight into the 
mechanisms involved in the stopping/continuing of the SWDs.
 Interestingly, Destexhe (1999) showed that, at least in his computational 
model, SWDs are part of a continuum of oscillatory states in which the peak frequency 
is determined by the relative values of GABAA and GABAB conductances in TC 
cells. This suggests that also the SWD peak frequency could be pharmacologically 
manipulated by using GABAergic drugs in WAG/Rij rats, which has not been explicitly 
investigated so far.
 In general, GABA agonistic drugs increase the occurrence of SWDs. 
Therefore, such drugs are not clinically used to treat absence epilepsy. Exceptions 
to this rule are the benzodiazepines, which decrease the occurrence of the SWDs 
probably due to their subunit speciﬁc activity (as mentioned earlier). 
 
Figure 7. A typical SWD of a drug-free WAG/Rij rat.
1 sec
300 μV
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1.4. The interaction between drugs
 Often in polytherapy research, the effects of a tested combination are 
compared with the monotherapy (each drug alone) effects without any regard for 
possible differences in drug load, i.e. the amount of drug exposure (Deckers et al., 
1997). Erroneous conclusions may be drawn if this drug load as a factor for differences 
in effect is neglected. The isobole method enables us to evaluate the interaction 
between the combined drugs (Loewe, 1953; Berenbaum, 1989; Greco et al., 1995). 
Essentially, the isobolic analysis is based on a comparison of equipotent drug doses. 
The potency of a drug or a combination of drugs is measured as a dose that produces 
a speciﬁed level of effect (EDx). Testing the interaction between a certain pair of drugs, 
requires determination of the potency of the combination and comparison of this 
potency with that of a theoretically additive combination. Therefore, equal directed 
dose response curves are needed for all three treatments (two monotherapies and the 
polytherapy).
 The isobole method, however, is of limited use for analysing drug interactions. 
In the ﬁrst place, the method only allows qualitative conclusions. Secondly, the method 
does not allow extrapolation from one dose combination to other dose combinations. 
Neither is the method convenient for extrapolation to other magnitudes of effect, which 
would only be allowed if all concentration-effect curves have the same Hill coefﬁcient 
(shape of the curve), i.e. the curves are parallel (van Rijn et al., 1999). Also, it is an 
empirical method and therefore not suitable to investigate which mechanism underlies 
the observed interaction (Van Rijn et al., 1999). Nevertheless, the isobole method is 
one of the few methods, if not the only method, that corrects for the used drug load, 
which is essential for conclusions about polytherapy interactions.
 The isobolic analysis is performed by ﬁrst determining the drug load of the 
combination deﬁned as      +      . a is the dose of drug A in the polytherapy, A is the 
dose of drug A in the monotherapy, b is the dose of drug B in the polytherapy, B is 
the dose of drug B in the monotherapy, needed to reach the chosen effect point 
(Berenbaum, 1989). Then, if an estimated drug load =1 the drug effects are purely 
additive (no interaction). If the drug load<1 then there is synergy. If the drug load >1 
then there is infra-additivity (Loewe, 1953; Berenbaum, 1989; Greco et al., 1995; 
van Rijn and Willems-van Bree, 2004). Next, T-tests can be performed to test for 
differences between the theoretically additive and the experimental polytherapy 
combination (Motulsky, 1995).
 The results of the isobolic analysis can also be shown in a so called 
isobologram (see ﬁgure 8).  Basically, in an isobologram the dose needed of a drug 
(A or B) in monotherapy to reach a chosen effect point is plotted as a point at an 
a     b
A    B
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axis (X- or Y-axis). Then the line of theoretical additivity for the chosen effect point is 
drawn, by connecting the monotherapy doses of drug A and drug B. The same is done 
for the 95% conﬁdence intervals (95% CIs) of these doses. Then the experimental 
polytherapy combination needed to reach the same effect, and its 95% CIs, are 
plotted. If this point lies signiﬁcantly (statistically tested) below the theoretical additive 
line, the interaction is synergistic, whereas the interaction is infra-additive when the 
point lies signiﬁcantly above the line.
 
Figure 8. An isobologram constructed for a single effect point. The open circles represent the doses needed in 
 the monotherapy to reach the effect point. Since the point of the experimental combination (black circle) 
 lies within the 95% conﬁdence intervals (95% CIs) of the theoretical additive combination (black line),
 there is an additive interaction between drug A and drug B for the chosen effect point.
1.5. Hazard rate analysis on (inter) SWD durations
 In practice, probability density functions are used to represent the relevant 
information in a data set (for instance the distribution of SWD durations). The 
probability density function can be estimated from the histogram of these data. This is 
illustrated in ﬁgure 9, in which the left panel shows the histogram of the data, and the 
right panel shows the probability density function that is estimated by this histogram. 
theoretical additive combination 
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Figure 9. Raw data represented in a histogram (left) and the estimated probability density function of these data 
 (right).
 However, the probability density function does not reveal information about the 
probability of observing an event at a certain time point. This instantaneous probability 
as a function of time, allows for interpretations about the changes over time in the 
mechanism responsible for the events. This information can not be directly observed 
by analysis of averages and the composing of histograms. Therefore, in order to 
characterise the mechanism(s) that govern the switching between normal brain 
activity and seizure activity, the data has to be further analysed by using other more 
sophisticated analyses, such as hazard rate analysis 
 Basically, the hazard rate is the probability that an event (starting or stopping 
of a SWD) occurs at the next instant of time given that it has not occurred yet. In ﬁgure 
10, it is shown how this probability must be calculated. In essence, the probability 
of an event occurring in the next instant of time (denoted by the surface of the grey 
striped area in ﬁgure 10) is divided by the probability that the event has not occurred 
yet (denoted by the surface of the black striped area in ﬁgure 10). We estimated the 
hazard rates from the data using a modiﬁcation of the estimation algorithm of Müller 
and Wang (1994) (for details see Maris et al., in press).
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Figure 10. A probability density function. The surface areas needed to calculate the hazard rate are indicated 
 (striped areas). 
 Then, the hazard rate of the inter SWD durations (time between two SWDs) 
can be interpreted as the instantaneous probability of starting a SWD given that it 
has not started yet. The hazard rate of the SWD durations can be interpreted as 
the instantaneous probability of stopping the SWD given that it has not stopped yet. 
The time course of these instantaneous probabilities reveals information about the 
underlying SWD starting and stopping mechanism(s) (Maris et al., inpress).
 In particular, if the hazard rate of the inter SWD durations is increasing, 
the probability of starting a seizure in the next small time interval (given that it has 
not started yet) is also increasing. In other words, over time the brain builds up a 
tendency to initiate a seizure. Alternatively, if this hazard rate is decreasing, then the 
probability of the seizure starting in the next instant of time is also decreasing. This 
means that, over time the brain loses its tendency to initiate a seizure. If the hazard 
rate of the SWD durations is increasing, then the probability of the SWD stopping in 
the next small time interval (given that it has not stopped yet) is also increasing. This 
indicates that the brain has some mechanism that, in a probabilistic way, prevents 
the seizures from lasting very long. Alternatively, if this hazard rate is decreasing, the 
probability of the SWD stopping in the bext instant of time is also decreasing. In other 
words, the brain gets stuck in the seizure. A constant hazard rate is a characteric of a 
brain mechanism without memory. More speciﬁcally, a constant hazard rate for SWD 
durations means that the probability of the SWD stopping does not change over time: 
it does not matter whether the seizure has been ongoing for a long time or has just 
started. A similar logic holds for a constant hazard rate for the inter SWD durations.
 Thus, the analysis of hazard rates of the distributions of the inter SWD 
durations and the SWD durations might reveal some new information on the 
mechanisms underlying the starting and stopping of the SWDs. Furthermore, by using 
Time (T)
F(T=t)
t    t+Δt
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this analysis tool on data obtained after pharmacological manipulation, more can be 
learned about the role of neurotransmitter systems in these underlying mechanisms.
1.6. Aim and outline of this thesis
The aim of this thesis:
 In this thesis, it was aimed to further evaluate the role of the GABAergic 
neurotransmission system in general in the mechanisms underlying absence epileptic 
SWDs. More speciﬁcally, the aim of this thesis is to investigate whether GABAergic 
neurotransmission is either quantitatively or qualitatively (or both) involved in the 
mechanisms underlying SWDs and whether this involvement is speciﬁcally determined 
by GABAA or GABAB mediated neurotransmission. 
The outline of this thesis:
 First, in order to evaluate the effects of GABAergic neurotransmission in 
general (both GABAA and GABAB mediated neurotransmission) on the properties 
of type II SWDs, the effects of vigabatrin on type II SWDs were investigated in ACI 
rats in chapter 2.  Next, in chapters 3 and 4, aimed to determine whether GABAA 
and GABAB mediated neurotransmission play a differential role in determining the 
different properties of SWDs, the effects of vigabatrin, the GABAA-ergic drug Org 
20599 (a neuroactive steroid) and the GABAB agonist R-baclofen on the SWD activity 
were investigated in WAG/Rij rats. The effects of GABAA and GABAB-ergic drugs 
and their combinations on classical variables such as incidence and durations and 
on a new variable describing the morphology of the SWDs were analysed. In order 
to evaluate the effects of GABAergic neurotransmission in general (both GABAA 
and GABAB mediated neurotransmission) on the properties of SWDs, in chapter 5 
the effects of vigabatrin on SWDs in WAG/Rij rats were investigated. In this chapter, 
hazard rate analysis was included, to speciﬁcally investigate the effect of GABAergic 
neurotransmission in general on the mechanism(s) that stop an ongoing SWD.
 Then, in chapter 6 the effects of vigabatrin on SWDs in WAG/Rij rats were 
simulated in a computational model. The aim was to evaluate the most likely 
mechanisms involved in the changes in SWD properties after vigabatrin. More 
speciﬁcally, the model output was used to evaluate whether the increase of GABA after 
vigabatrin is either homogeneous or heterogeneous throughout the brain, and in case 
of a heterogeneous increase it was hypothesised which speciﬁc region(s) are mostly 
affected by vigabatrin. Also, hazard rate analysis was used to investigate the effects on 
the mechanism(s) that stop an ongoing SWD and the mechanism(s) that start a SWD. 
The question remained whether there is a speciﬁc role for either GABAA or GABAB 
mediated neurotransmission in the mechanisms that underlie the starting and stopping 
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of the SWDs. Therefore, in chapter 7 the effects of several GABAergic drugs on the 
SWD activity in WAG/Rij rats were investigated. Again, hazard rate analysis was used 
to investigate the effects on the mechanism(s) that stop an ongoing SWD and the 
mechanism(s) that start a SWD.
 In chapter 8 (the general discussion), the most interesting and striking 
results are summarised and their implications are discussed. Also, some possible 
mechanisms underlying SWDs are proposed, and the effects that the GABAergic 
drugs might have on these proposed mechanisms are discussed. 
 

Bouwman B.M., van den Broek P.L.C., van Luijtelaar G. and van Rijn C.M. (2003).
Published in: Neuroscience Letters, 338: 177-180.
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The effects of vigabatrin on type II 
spike wave discharges in rats
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Abstract
 The antiepileptic drug vigabatrin increases GABA concentrations by inhibiting 
GABA transaminase. The effects of vigabatrin on type II spike wave discharges 
(SWDs) in the EEG of ACI rats were studied in order to learn more about the effects 
of altering GABA concentration on SWDs. The incidence of type II SWDs increased 
after vigabatrin (60 /h) as compared to saline treatment (3.7 /h). This effect appeared 
with a halftime of 100 minutes. The duration of type II SWDs increased after vigabatrin 
(1.52 s) as compared to saline treatment (1.04 s), but the peak-frequency of the type 
II SWDs decreased after vigabatrin (5.6 Hz) as compared to saline treatment (7.5 Hz). 
Thus, vigabatrin alters the type II SWD morphology. These results are in agreement 
with predictions of Destexhe’s theoretical model, modulating both GABAA and GABAB 
conductances. 
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2.1. Introduction
 In the electroencephalogram (EEG) of many in- and outbred strains of rats, 
bursts of rhythmic sharp activity with a frequency of approximately 8 Hz can be seen 
(Inoue et al., 1990; Willoughby and Mackenzie, 1992). This activity is commonly called 
spike wave discharges (SWDs). Van Luijtelaar and Coenen (1986) reported two types 
of SWDs in the cortical EEG of a particular inbred strain of rats, the WAG/Rij rat. 
Type I SWDs are generalized and symmetrical over the two hemispheres and have 
a mean duration of 5 (range 1-30) seconds and the mean frequency within a burst is 
8.7 (range 7.5-9.5) Hz. Type II SWDs are more localised in the parietal cortex, and 
have a opposite polarity, a mean duration of 0.8 (range 0.5-2.0) seconds, and a slightly 
lower mean frequency in a range of 6.3-8.0 Hz (van Luijtelaar and Coenen, 1986; 
Midzianovskaia et al., 2001).
 Little is known about the pharmacological properties of the type II SWDs. 
There are only data which show that the incidence of this type of SWDs (but also 
type I SWDs) was dose-dependently increased by the GABA-reuptake inhibitor 
tiagabine (Coenen et al, 1995), and that type II SWD incidence was increased after 
the administration of the dopamine agonist apomorphine whereas type I SWDs were 
completely suppressed (Midzianovskaia et al., 2001). Tiagabine directly increases 
GABA concentrations (Schachter, 1999), thus affecting both GABAA and GABAB 
conductances while the non-selective dopamine receptor agonist apomorphine 
(Bristow et al., 1997) indirectly increases GABA concentrations (Deransart et al., 1998; 
Grobin and Deutch, 1998) even in the parietal cortex (Wedzony et al., 2000), thus also 
affecting both GABAA and GABAB conductances.
 It has been suggested that the balance between GABAA and GABAB 
conductance is essential for the control of SWDs (Destexhe, 1999). An increase in 
GABA concentration can alter the balance between GABAA and GABAB conductances 
since the afﬁnity of GABA for both receptor types differ (Chu et al., 1990). Possibly this 
balance is differentially affected by tiagabine and apomorphine, therefore resulting in 
the different effects of these two drugs on SWDs.
In order to learn more about the effects on type II SWDs of altering the GABA 
concentration, rats were treated with vigabatrin. Vigabatrin is an anti-epileptic drug 
that irreversibly inhibits GABA transaminase (Hammond and Wilder, 1985), and thus 
increases GABA concentration, affecting both GABAA and GABAB conductances. 
Since the rise of GABA concentration as a result of vigabatrin injection has a slow 
onset (Tong et al., 2000), the effects on SWDs were measured up to six hours after 
injection. Since ACI rats (agouti) (Festing, 1979) have almost no type I SWDs (Inoue et 
al., 1990) but do have type II SWDs (Schridde, personal communication) this strain of 
rats was used in the present experiment.
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2.2. Materials and Methods
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
 Male ACI rats (n=6), 8 months old, with a mean body weight of 254 g 
(S.D.=17), were used. Animals were individually housed in Macrolon cages and were 
maintained on a reversed 12-h light-dark cycle with lights on at 20.00 h. Food and 
water were available ad libitum. A permanent cortical tripolar electrode (Plastics One) 
was implanted under complete isoﬂurane anaesthesia, one electrode in the frontal 
region (coordinates with the skull surface ﬂat and bregma zero-zero: A 2.0, L 3.5), 
and the other in the parietal region (A –6.0, L 4.0, (Paxinos and Watson, 1997)). The 
ground electrode was placed over the cerebellum. After the surgery, the animals were 
allowed to recover for at least 2 weeks.
 Rats were put into transparent recording cages, connected to an EEG cable, 
and habituated to the experimental conditions for 1 h.  Experimental sessions were 
performed between 10:00 and 17:00 h on two separate days with 7 days between 
experimental days. The rats were injected i.p. with saline (2 ml/kg) or 500 mg/kg 
vigabatrin (2 ml/kg) . Each rat received both treatments, counterbalanced over the 
two experimental days. Directly after the injections the EEG was recorded during the 
following 6 hours. The EEG in a bandwidth between 0.1 and 100 Hz, was digitalized 
with a sample frequency of 512 Hz, and stored for an off-line analysis using the 
Windaq system (DATAQ Instruments, Akron, OH). The type II SWDs were marked 
after visual inspection based on the criteria for standard type II SWDs as proposed by 
Van Luijtelaar and Coenen (1986).
 SWD incidence and duration were determined per block of one hour. The 
SWD morphology was analysed, using a Fast Fourier Transform procedure with a 
window of 1 second, starting at the beginning of the type II SWD. Statistical analyses 
on the SWD incidence were performed, using a Repeated Measures procedure 
(SPSS) with Greenhouse-Geisser correction (with time as within subject factor and 
treatment as between group factor, α=0.05). Statistical analyses on the SWD duration 
and peak frequency of the aggregated data per treatment per hour were performed, 
using an ANOVA procedure (SPSS) (with both time and treatment as between factors, 
α=0.05). To describe the Time*Treatment interactions, posthoc, a sigmoid model and 
an exponential model were ﬁtted versus a horizontal linear model and best ﬁts were 
tested with F-tests (Graphpad Prism).
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2.3. Results
2.3.1. Type II SWD incidence 
 Means and 95% conﬁdence intervals of the averaged number of SWDs per 
hour per rat per treatment are illustrated in ﬁgure 1 (upper panel). Statistical analyses 
showed a main effect of Treatment (F(1,10)=6.60; P=0.028) and an interaction effect 
of Time*Treatment (F(5,50)=3.61; P=0.048). The horizontal model ﬁtted best to the 
data of the saline group (mean incidence=3.7 /h, S.E.=0.7 /h), while the sigmoid model 
ﬁtted best to the data of the vigabatrin group (P<0.05) (t1/2=100 min., S.E.=28 min.; 
maximal incidence=60 /h, S.E.=9 /h).
2.3.2. Type II SWD duration
 Means and 95% conﬁdence intervals of the average duration of SWDs per 
hour per treatment are illustrated in ﬁgure 1 (middle panel). Statistical analyses 
showed a main effect of Treatment (F(1,1700)=104.7; P<0.001) and an interaction 
effect of Time*Treatment (F(5,1700)=4.491; P<0.001). The horizontal model ﬁtted 
best to the data of the saline group (mean duration=1.04 s, S.E.=0.05 s), while the 
exponential model ﬁtted best to the data of the vigabatrin group (P<0.05) (t1/2=24 min., 
S.E.=9 min.; maximal duration=1.52 s, S.E.=0.05 s).
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Figure 1. Mean type II SWD incidence (n=6 rats), duration and peak frequency as a function of time and 
 treatment (with 95% conﬁdence intervals). For all the variables a horizontal linear model ﬁtted best to 
 the saline data. For the incidence of the vigabatrin group a sigmoid model ﬁtted best, whereas for the 
 duration and peak frequency an exponential model ﬁtted best to the vigabatrin data.
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2.3.3. Type II SWD morphology
 A typical type II SWD per treatment 6 hours post injection is shown in ﬁgure 2 
(upper panel). The power spectra for these type II SWDs are shown in ﬁgure 2 (lower 
panel). The mean peak frequency per rat for the two treatments was determined. 
The mean peak frequency per hour per treatment is illustrated in ﬁgure 1 (lower 
panel). Statistical analyses showed a main effect of Time (F(5,1700)=9.89; P<0.001), 
a main effect of Treatment (F(1,1700)=279.3; P<0.001) and an interaction effect of 
Time*Treatment (F(5,1700)=7.46; P<0.001). The horizontal model ﬁtted best to the 
data of the saline group (mean peak frequency=7.50 Hz, S.E.=0.17 Hz), while the 
exponential model ﬁtted best to the data of the vigabatrin group (P<0.05) (t1/2=29 min., 
S.E.=10 min.; minimal peak frequency=5.61 Hz, S.E.=0.07 Hz).
 
Figure 2. A typical type II SWD 6 hours post injection of the saline and the vigabatrin group and the 
 corresponding power spectra.
2.4. Discussion
 The objective of this study was to investigate the effects of vigabatrin on type II 
SWDs in rats. The incidence and duration of type II SWDs were signiﬁcantly increased 
after vigabatrin as compared to the saline condition. The peak frequency of the type 
II SWDs was decreased after vigabatrin as compared to the saline condition. Thus, 
vigabatrin alters the type II SWD morphology.
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 The time dependency of the effects agrees with the time dependency of 
the enhancement of GABA concentrations after vigabatrin (Tong et al., 2000). 
Furthermore, the increase in type II SWD incidence after vigabatrin agrees with the 
reported increase in type II SWD incidence after tiagabine (Coenen et al., 1995). This 
supports the idea that SWDs are dependent on the balance between GABAA and 
GABAB transmission, since both drugs result in an increase of GABA concentration, 
inﬂuencing both GABAA and GABAB conductance. Vergnes et al. (1984) reported that 
vigabatrin enhances the SWD incidence in GAERS, another well known model of 
absence epilepsy in rats. Thus, the effects of vigabatrin on type I and type II SWDs 
agree with the effects of tiagabine. Also, Vergnes et al. (1984) brieﬂy mentioned 
frequency modulation of SWDs in GAERS after vigabatrin.
 Interestingly, the decreased peak frequency after vigabatrin injection shown in 
the present experiment agrees with the simulated data based on alterations in GABAA 
and GABAB conductance (Destexhe, 1999). Thus, our in vivo data also support the 
proposed theory that fast and slow spike-and-wave oscillations are part of a continuum 
of oscillatory states, in which frequency and duration are determined by GABAA and 
GABAB conductances in thalamocortical relay cells (Destexhe, 1999).
 Frequency modulation of SWDs is suggested to be a possible mechanism 
involved in the interruption of an ongoing discharge (Midzianovskaia et al., 2001). 
This suggestion is not supported by the data of this experiment. In this experiment, 
vigabatrin injection results in a decrease in type II SWD peak frequency but an 
increase in type II SWD duration. Therefore, a lower peak frequency does not 
necessarily result in a shorter type II SWD duration. However, this study used 
pharmacological manipulations and therefore can not be used as a direct comparison 
for the physiological situation.
 In conclusion, vigabatrin injection results in an increased incidence and 
duration and a decreased peak frequency of type II SWDs. The combination of 
increased duration and decreased peak frequency, suggests evidence against the idea 
of frequency modulation as a mechanism involved in the interruption of an ongoing 
discharge. These data are in agreement with predictions of a theoretical model 
(Destexhe, 1999) indicating the importance of good theoretical models as helpful tools 
in the search for understanding in the mechanism that generates and controls the 
SWDs.
 
3
Vigabatrin and neuroactive steroid 
Org 20599 interact additively,  
on absence epileptic spike and 
wave discharges in WAG/Rij rats; 
an isobolic analysis
 
Bouwman B.M., Stronks H.C. and van Rijn C.M. (in preparation).
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Abstract 
 In vitro, GABA and the GABAergic neuroactive steroid Org 20599 were 
shown to act synergistically in the binding at the GABAA receptor. To test whether 
this in vitro interaction can be translated to the in vivo situation, effects on spike and 
wave discharges after GABA transaminase inhibitor vigabatrin and Org 20599 were 
investigated in WAG/Rij rats. The effects of vigabatrin (65-500 mg/kg i.p.) and Org 
20599 (8-60.8 mg/kg i.p.) were compared with the effects of their combination (dose 
ratio 8.2:1). Isobolic analyses were performed to describe the interactions. Vigabatrin, 
Org 20599 and their combination dose dependently increased the SWD incidence, 
whereas only Org 20599 increased the average SWD duration. Both vigabatrin and 
the polytherapy combination dose dependently decreased the SWD peak frequency, 
suggesting that this effect is GABAB related. The interaction between vigabatrin and 
Org 20599 on the SWD incidence was shown to be additive, showing that in vitro 
interactions can not be simply translated to the in vivo situation. 
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3.1. Introduction
 Most patients (about 70%) with epilepsy can be effectively treated with a single 
anti-epileptic drug (Kwan and Brodie, 2002). Unfortunately, some patients (30%) 
do not respond to a single anti-epileptic agent, even when the drug is prescribed 
at the maximally tolerated dose (Perucca, 1995). Many physicians will try to treat 
these patients with combinations of anti-epileptic drugs (Kwan and Brodie, 2002). 
A combination of drugs would be considered advantageous if the two drugs show 
additive therapeutic (anti-epileptic) effects with infra-additivity (antagonistic) for the 
other (unwanted) effects, or supra-additive (synergistic) therapeutic effects with 
additivity for the other effects. Ideally, the drugs to be combined and their doses can 
be chosen on a rational basis. In rational polytherapy, drugs are combined based on 
knowledge of their pharmacological characteristics (Deckers et al., 2000).
 The WAG/Rij rat, an inbred strain of rats, is recognised as an animal model 
of human absence epilepsy (Van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 2003). The absence epileptic human electroencephalogram as well as that 
of animal models of absence epilepsy are characterised by generalised spike and 
wave discharges (SWDs).
 Gamma-aminobutyric acid (GABA) is generally believed to be implicated in 
the mechanisms of initiation and propagation of (absence) epileptic seizures (Crunelli 
and Leresche, 2002). The GABAergic neurotransmission system contains two major 
receptor types, the GABAA and GABAB receptors. The GABAA receptor is an ionotropic 
receptor with a chloride channel, whereas the GABAB receptor is a metabotropic 
receptor coupled to calcium and potassium channels (Bowery et al., 2002). The 
GABAA and GABAB receptors can be activated by their natural agonist GABA. Besides 
the binding site for GABA the GABAA receptor contains several different binding sites 
for allosteric modulators such as barbiturates, benzodiazepines and neuroactive 
steroids (Korpi et al., 2002).
 Interestingly, it has been suggested that the balance between GABAA and 
GABAB conductance is essential for the control of SWDs (Destexhe, 1999; Destexhe 
and Sejnowski, 2003). Therefore, targeting both GABAA and GABAB receptors, but one 
more than the other, might be interesting for research on polytherapy. Endogenous 
GABA concentrations can be increased by use of vigabatrin, an irreversible GABA 
transaminase inhibitor (Hammond and Wilder, 1985). By increasing endogenous 
GABA concentrations both the GABAA and GABAB neurotransmission is favoured. 
GABAA neurotransmission can be allosterically enhanced by the neuroactive steroid 
Org 20599 (Hill-Venning et al., 1996). Interestingly, in vitro the combination of GABA 
and neuroactive steroid Org 20599 was shown to have a synergistic interaction at the 
GABAA receptor (van Rijn et al., 1999). Therefore, the combination of vigabatrin and 
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Org 20599 is expected to tip the balance between GABAA and GABAB more towards 
GABAA.  Also, if the in vivo effects are a result of the effects of the drugs on the GABAA 
neurotransmission, we expect that the observed synergistic interaction in vitro might 
also be translated to the in vivo situation.
 Vigabatrin has been shown to increase the SWD activity in rats (Vergnes et 
al., 1984; Marescaux et al., 1992b, Bouwman et al., 2003b, Bouwman et al., 2003c). 
Furthermore, vigabatrin was shown to decrease the peak frequency of the SWDs 
(Bouwman et al., 2003b; Bouwman et al., 2003c). Neuroactive steroids have also been 
shown to increase the SWD activity in rats (Budziszewska et al., 1999). Interestingly, 
Destexhe (1999) suggests that especially GABAB neurotransmission determines the 
peak frequency of the SWDs, as long as there as enough GABAA neurotransmission 
to sustain the SWDs. Therefore, the neuroactive steroid Org 20599 is not expected 
to decrease the peak frequency of the SWDs, whereas the combination of vigabatrin 
and Org 20599 is expected to decrease the peak frequency of the SWDs to the same 
degree as vigabatrin alone. 
 In the present study the effects on the SWD incidence, average SWD duration, 
and on the SWD peak frequency, of several doses of vigabatrin and Org 20599 
monotherapy and those of the combination of these drugs were measured in WAG/Rij 
rats. Where applicable the results are analysed using the isobolic method (Greco et 
al., 1995).
3.2. Materials and methods
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
3.2.1. Drugs
 Vigabatrin (Yamanouchi Pharma B.V., The Netherlands) and Org 20599 
(Organon Laboratories Ltd., Scotland, UK) were dissolved in saline (0.9%). Saline was 
used as the control for vigabatrin, Org 20599 and polytherapy treatment. Both drugs 
were administered intraperitoneally (i.p.), both vigabatrin and Org 20599 in a volume 
of 12.5 ml/kg, to avoid effects of great osmolarity differences (Bouwman et al., 2003a). 
For vigabatrin the following doses were used: 0 (saline), 65, 98, 148, 222, 333 or 500 
mg/kg. The Org 20599 treatment consisted of the doses: 0 (saline), 8, 12, 18, 27, 40.5 
or 60.8 mg/kg. For the polytherapy, the following combinations (vigabatrin/Org 20599) 
were used: 65/8, 98/12, 148/18, 222/27 or 333/40.5 mg/kg (dose ratio=8.2:1). 
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3.2.2. Animals and experimental conditions
 Experiments were performed in 45, 9-months-old male WAG/Rij rats with an 
average weight of 331 g (S.E.=2.4 g). The rats were maintained on a reversed 12-h 
light-dark cycle with lights on at 20.00 h. The rats had ad libitum access to food and 
water.
 Each dose or combination was tested in 6 animals; a total of 108 observations 
were made. To limit the number of animals needed, each rat participated in up to three 
experimental sessions (3 treatments) with at least a 7 day interval between each 
session. Rats were semi-randomly assigned to up to three treatments, in a way that 
none of the rats received only control or high dose treatments. The selected treatments 
per rat were randomised over the three sessions. Experimental sessions were 
performed between 9.00 and 16.15 h. The experiment was performed on 28 separate 
experimental days, testing 4 rats per day. For the experimental design see table 1. Per 
experimental day, each rat received 2 injections: at 9.00 h saline or vigabatrin and at 
15.00 h saline or Org 20599. 
 Table 1. The experimental schedule.
 9.00 h injection 15.00 h injection Observed period (15.15–15.45 h)
 Saline Saline Control data
 Vigabatrin Saline Vigabatrin monotherapy data
 Saline Org 20599 Org 20599 monotherapy data
 Vigabatrin Org 20599 Polytherapy data
3.2.3 Surgery and EEG recording
 Isoﬂurane anaesthesia was used during the implantation of a tripolar EEG 
electrode (Plastics One MS-332/2-A) on the cortical surface: one electrode on the 
frontal region (coordinates with skull surface ﬂat and bregma zero-zero: A2.0 L3.5) 
and a second one in the parietal region (A-6.0 L4.0) (Paxinos and Watson, 1997). 
The reference electrode was placed over the cerebellum. The rats were allowed to 
recover from surgery for at least 14 days before experimentation began. The rats 
were habituated to the experimental setting during 30 min per day on two successive 
days before experimentation. On experimental days, 4 rats were placed in separate 
recording cages (19x19x40 cm) and connected with leads through swivels to an 
ampliﬁer and a computer-based data acquisition system (Dataq Instruments, OH, 
USA). The EEG signals in a bandwidth between 1 and 100 Hz, were sampled with a 
frequency of 512 Hz.
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 The EEG of the rats was recorded continuously for a 30-min period, beginning 
15 minutes after the injection at 15.00 h. This period (6 h post vigabatrin injection) 
was chosen since GABA transaminase levels reach a minimum and GABA levels are 
maximally increased 4 h after vigabatrin injection, and these levels are maintained for 
24 h (Hammond and Wilder, 1985). Ofﬂine, the incidence and average duration of the 
spike and wave discharge activity, for the observed 30-min period, was determined 
by visual inspection based on the criteria for standard spike and wave discharges 
as proposed by Van Luijtelaar and Coenen (1986). The SWD peak frequency was 
determined using a Fast Fourier Transform procedure in Brain Vision Analyzer version 
1.04 (Brain Products GmbH, Germany) with a window of 2 s, starting at the beginning 
of the SWD. 
3.2.4. Statistics
 To evaluate the dose-response relationship the sigmoid Emax model was ﬁtted 
to the data versus a horizontal linear model, and best ﬁts were analysed with F-tests, 
using Graphpad Prism 4.02 for Windows (GraphPad Software, San Diego, California 
USA). Since most of the here presented data sets do not have measured data points in the 
full range of the curve, any interpretation of the Emax is hazardous. Therefore, effect points 
within the measured range were chosen; the ED(2xbaseline), the ED(3xbaseline), ED(2 s increase), 
or the ED(1Hz decrease) were estimated, when appropriate. The ED(2x baseline) and ED(3xbaseline) 
were deﬁned as the dose necessary to obtain two or three times the baseline value 
respectively. The ED(2 s increase) was deﬁned as the dose necessary to obtain 2 seconds 
increase of the baseline duration. The ED(1Hz decrease) was deﬁned as the dose necessary 
to obtain 1 Hz decrease of the baseline frequency. When the obtained curve ﬁts well 
on the data, these EDs are practically independent of the Emax. 
 When equal directed effect curves were obtained, the type of interaction 
between the drugs was analysed using the isobolic method (Greco et al., 1995); 
visually by plotting the ED(2x baseline) or the ED(3x baseline) values on an isobologram and 
numerically by comparing the drug load, needed to reach the chosen effect point, of 
the observed polytherapy with the drug load of the theoretical additive combination.
 The drug load deﬁned as             +             was determined. gvg is the dose 
of vigabatrin in the polytherapy, GVG is the dose of vigabatrin in the monotherapy, 
org is the dose of ORG 20599 in the polytherapy, ORG is the dose of ORG 20599 
in the monotherapy, needed to reach the chosen effect point (Berenbaum, 1989). If 
an estimated drug load =1 then the drug effects are purely additive (no interaction). 
If the drug load<1 then there is suppra-additivity (synergy). If the drug load >1 then 
there is subadditivity (antagonism) (Greco et al., 1995). T-tests were performed to test 
 gvg        org
GVG     ORG
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for differences between the theoretically additive and the experimental polytherapy 
combination (Motulsky, 1995).
3.3. Results
3.3.1. Effects on the SWD incidence
 Figure 1 shows the means with the standard errors of the SWD incidence 
per dose of vigabatrin, Org 20599 and their combination. The sigmoid Emax model  
ﬁtted best through the data of the vigabatrin (F(2,38)=8.66; P<0.001) and Org 20599 
(F(2,40)=23.5; P<0.0001) monotherapies and also their combination (F(2,33)=12.5; 
P<0.0001) (see table 2 for ﬁt parameters).
 
Figure 1. The means with the standard errors of the SWD incidence per dose of vigabatrin, Org 20599 and their 
 combination.
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Table 2. Isobolic analysis on the SWD incidence.
Vigabatrin Org 20599 Theoretical Experimental
(GVG) (ORG) additive combination
(GVG/ORG) (GVG/ORG)
SWD Emax
b 39.1 41.9 44.8
incidence 95% CIs 20.0 - 58.2 27.3 - 56.4 16.6 - 72.9
Bottom/
Control valuea
                   
11.3
                         
11.3
                      
11.3
Hillb 4.33 2.06 1.73
95% CIs -0.06 - 8.79 0.21 - 3.91 -0.08 - 3.53
ED(2x baseline)
b 
(mg/kg)
                    
237
                   
14.0
                         
  77.4/9.42
             
80.4/9.78
95% CIs 
(mg/kg)
                    
140 - 400
                   
7.85 - 25.0
45.9 - 131/ 
5.28 - 16.8
33.7 - 192/
4.09 - 23.3
Drug load 1.0 1.0 1.0 1.04
95% CIs 0.59 - 1.69 0.56 - 1.78 0.57 - 1.75 0.43 - 2.48
ED(3x baseline)
b 
(mg/kg)
                    
364
                         
30.2
               
148/18.0
            
182/22.1
95% CIs 
(mg/kg)
                    
197 - 675
                   
17.1 - 53.3
79.8 - 274/
10.2 - 31.7
86.9 - 381/
10.6 - 46.4
Drug load 1.0 1.0 1.0 1.23
95% CIs 0.54 - 1.85 0.57 - 1.77 0.56 - 1.80 0.59 - 2.58
The curve ﬁt parameters and the corresponding 95% conﬁdence intervals for the vigabatrin and Org 20599 mono-
therapies, the theoretical additive combination and the experimental combination. a indicating ﬁxed parameters, 
and b indicating ﬁtted parameters, separately ﬁtted for each treatment.
3.3.1.1. Isobolic analysis of the SWD incidence
 The chosen effect points for the isobolic analysis of the effects of the 
monotherapy and polytherapy treatments on the SWD incidence were the ED(2xbaseline) 
and ED(3xbaseline). Both ﬁgure 2 and table 2 show the ED(2xbaseline) and ED(3xbaseline) with the 
95% CIs of vigabatrin, Org 20599 and their experimental combination for increasing 
the SWD incidence. Furthermore, they show the theoretical additive combination and 
the 95% CIs needed to obtain these ED values. The normalised ED(2xbaseline) (t(10)=0.06; 
P=0.95) and ED(3xbaseline) (t(10)=0.39 ;P=0.71), i.e. drug loads, for the experimental 
combination are not signiﬁcantly different from that of the theoretical additive 
combination. Thus, there was no evidence for another than an additive interaction 
between vigabatrin and Org 20599 on this variable for the effects of 2 and 3 times the 
baseline.
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Figure 2. The isoboles of the ED(2xbaseline) and ED(3xbaseline) on the SWD incidence for the combination of 
 vigabatrin and Org 20599, showing the theoretical additive combination and the experimental 
 combination with the 95% conﬁdence intervals.
3.3.2. Effects on the average SWD duration
 Figure 3 shows the means with the standard errors of the average SWD 
duration per dose of vigabatrin, Org 20599 and their combination. The horizontal 
linear model ﬁtted best through the data of the vigabatrin monotherapy (F(3,37)=0.35; 
P>0.05) and the polytherapy combination (F(3,32)=0.17; P>0.05), whereas the 
sigmoid Emax model  ﬁtted best through the data of the Org 20599 monotherapy 
(F(2,39)=5.39; P<0.01) (see table 3 for ﬁt parameters).
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Figure 3. The means with the standard errors of the average SWD duration per dose of vigabatrin, Org 20599 
 and their combination.
 
3.3.3. Effects on the SWD peak frequency
 Figure 4 shows the means with the standard errors of the SWD peak frequency 
per dose of vigabatrin, Org 20599 and their combination. The sigmoid Emax model ﬁtted 
best through the data of the vigabatrin monotherapy (F(2,36)=32.6; P<0.0001) and 
the polytherapy combination (F(2,31)=13.9; P<0.0001), whereas the horizontal linear 
model  ﬁtted best through the data of the Org 20599 monotherapy (F(2,40)=0.02; 
P>0.05) (see table 3 for ﬁt parameters).
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Figure 4. The means with the standard errors of the SWD peak frequency per dose of vigabatrin, Org 20599 and
 their combination.
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Table 3. Fit parameters of the treatments on the average SWD duration and the SWD 
               peak frequency.
Vigabatrin
(GVG)
Org 20599
(ORG)
Experimental
combination
(GVG/ORG)
Average SWD
duration
Horizontal 
Linear 
model
Intercept/
Control valuea
Slopea
5.17
0.0 x
5.17
0.0
Sigmoid Emax 
model
Bottom/
Control valuea x 5.17 x
Emax
b x 8.65 x
95% CIs 
(mg/kg) x 6.99 - 10.3 x
Hillb x 2.79 x
95% CIs 
(mg/kg) x -2.82 - 8.41 x
ED(2 s increase) 
(mg/kg) x 13.1 x
95% CIs x 7.35 - 23.3 x
SWD peak
frequency
Horizontal 
Linear model
Intercept/
Control valueb x 8.97 x
Slopeb x 0.0 x
Sigmoid Emax 
model
Top/Control 
valuea 8.97 x 8.97
Emax
b 5.87 x 7.51
95% CIs 
(mg/kg) 3.19 - 8.56 x 5.35 - 9.67
Hillb -2.37 x -3.99
95% CIs 
(mg/kg) -4.85 - 0.11 x -11.8 - 3.87
ED(1 Hz decrease)
b 
(mg/kg) 228 x 290/35.3
95% CIs 179 - 289 x 210-400/
25.6 - 48.8
 
The curve ﬁt parameters and the corresponding 95% conﬁdence intervals for the vigabatrin and Org 20599 mono-
therapies and the experimental combination. a indicating ﬁxed parameters, and b indicating ﬁtted parameters.
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3.4. Discussion
 We investigated the effects of the interaction between vigabatrin and Org 
20599 on SWDs in the absence epileptic WAG/Rij rat. Vigabatrin, Org 20599 and 
their combination dose dependently increased the SWD incidence, whereas only 
Org 20599 increased the average SWD duration. Furthermore, only vigabatrin and 
the polytherapy combination dose dependently decreased the SWD peak frequency, 
whereas Org 20599 had no effect.
 The increased SWD incidence after vigabatrin agrees with our earlier ﬁndings 
(Bouwman et al., 2003b; Bouwman et al., 2003c) and with ﬁndings of Vergnes et 
al. (1984) and Marescaux et al. (1992b). The increased SWD incidence after the 
GABAergic neuroactive steroid Org 20599 agrees with ﬁndings of Budziszewska et al. 
(1999), who tested the GABAergic neuroactive steroid allopregnanolone.
 Since on the SWD incidence similarly directed curves of the treatments were 
obtained, the isobolic analysis could be performed. This isobolic analysis showed 
that there was an additive interaction between vigabatrin and Org 20599 on the SWD 
incidence for the effects of 2 and 3 times the baseline. These data suggest that a 
combination of a GABA transaminase inhibitor and a GABAB agonist have no more 
SWD activity increasing potential than would be expected based on their SWD activity 
increasing potential as monotherapies.
 Interestingly, in vitro Org 20599 and GABA were shown to interact 
synergistically at the GABAA receptor (van Rijn et al., 1999). The fact that in vivo, 
measuring SWD activity, we found no synergistic interaction between vigabatrin and 
Org 20599 suggests that the observed additive interaction, between GABA, increased 
due to vigabatrin, and Org 20599, is possibly not only the result of the actions on 
the GABAA receptor. Instead, the observed additive interaction might be due to 
pharmacokinetic interactions or pharmacodynamic interactions on other receptors, 
since the in vivo system is much more complex than in vitro systems. So, in vitro 
results can not be directly translated to the in vivo situation. 
  The decreased SWD peak frequency after vigabatrin agrees with our 
earlier ﬁndings (Bouwman et al., 2003b; Bouwman et al., 2003c). Furthermore, the 
decreased SWD peak frequency after vigabatrin and the combination, but not after Org 
20599 agrees with suggestions of Destexhe (1999) that the GABAB neurotransmission 
determines the peak frequency of the SWDs, as long as there is sufﬁcient GABAA 
neurotransmission to sustain the SWDs. Indeed, to our knowledge, no (other) GABAA 
agonists are shown to decrease the peak frequency of SWDs, therefore the effect of 
vigabatrin is likely to be due to its increasing effect on the GABAB neurotransmission. 
 In conclusion, the interaction between vigabatrin and Org 20599 on the 
incidence of the SWDs was shown to be additive, showing that in vitro results can not 
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be simply translated to in vivo effects. Furthermore, the decreased peak frequency 
after vigabatrin and not after Org 20599, further supports the hypothesis that the 
GABAB neurotransmission determines the peak frequency of the SWDs.
 
 
4
The interaction between 
vigabatrin and R-baclofen on 
absence epileptic spike and wave 
discharges in WAG/Rij rats; 
an isobolic analysis
Bouwman B.M., Bruinsma I.B. and van Rijn C.M. (submitted).
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Abstract
 To test whether there is an interaction between two gamma-aminobutyric acid 
(GABA) -ergic drugs, targeting the GABAA and/or GABAB receptors, effects on spike 
and wave discharges were investigated in WAG/Rij rats. The effects of vigabatrin (65-
500 mg/kg i.p.) and R-baclofen (0.65-5 mg/kg i.p.) were compared with the effects of 
their combination (dose ratio 100:1). Isobolic analyses were performed to describe the 
interactions. Vigabatrin, R-baclofen and their combination dose dependently increased 
the SWD incidence and the total SWD duration, whereas only R-baclofen increased 
the average SWD duration. Furthermore, all treatments dose dependently decreased 
the SWD peak frequency. The interaction between vigabatrin and R-baclofen on the 
SWDs was shown to be either infra-additive or additive, dependent on the variable and 
effect point under investigation. These data suggest an interesting role for the interplay 
between GABAA and GABAB neurotransmission in the genesis and control of SWDs.
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4.1. Introduction
 Most patients (about 70%) with epilepsy can be effectively treated with a single 
anti-epileptic drug (Kwan and Brodie, 2002). Unfortunately, some patients (30%) do 
not respond to a single anti-epileptic agent, even when the drug is prescribed at the 
maximally tolerated dose (Perucca, 1995). Many physicians will try to treat these 
patients with combinations of anti-epileptic drugs (Kwan and Brodie, 2002; Patsalos 
et al., 2002). A combination of drugs would be considered advantageous if the drugs 
show additive therapeutic (anti-epileptic) effects with infra-additivity (antagonistic) for 
the other (unwanted) effects, or supra-additive (synergistic) therapeutic effects with 
additivity for the other effects (Van Rijn et al., 2004). Ideally, the drugs to be combined 
and their doses can be chosen on a rational basis (Van Rijn and Willems-van Bree, 
2004). In rational polytherapy, drugs are combined based on knowledge of their 
pharmacological characteristics (Deckers et al., 2000). However, given the incomplete 
knowledge of these characteristics, the drugs for the combinations are often chosen 
on clinical empirical grounds (Patsalos et al., 2002). Therefore, fundamental research 
to select relevant combinations is still needed.
 The WAG/Rij rat, an inbred strain of rats, is recognised as an animal model 
of human absence epilepsy (Van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 2003). The absence epileptic human electroencephalogram as well as that 
of animal models of absence epilepsy are characterised by generalised spike and 
wave discharges (SWDs).
 Gamma-aminobutyric acid (GABA) is generally believed to be implicated 
in the mechanisms of initiation and propagation of (absence) epileptic seizures 
(Crunelli and Leresche, 2002). The GABAergic neurotransmission system contains 
two major receptor types, the GABAA and GABAB receptors. The GABAA receptor 
is an ionotropic receptor with a chloride channel, whereas the GABAB receptor is a 
metabotropic receptor coupled to calcium and potassium channels (Bowery et al., 
2002). Both GABAA and GABAB receptors are activated by their natural agonist GABA. 
The maximal conductance activated by GABAB receptors is much smaller than that 
activated by GABAA receptors (Sodickson and Bean, 1996). Indeed, GABAB-mediated 
inhibitory postsynaptic potentials require stronger or more sustained stimulation than 
GABAA-mediated responses do (Kim et al., 1997). Thus, small increases in GABA 
concentrations probably result in in vivo effects dominated by GABAA-mediated 
responses.
 Interestingly, it has been suggested that the balance between GABAA and 
GABAB conductance is essential for the control of SWDs (Destexhe, 1999; Destexhe 
and Sejnowski, 2003). Therefore, targeting both GABAA and GABAB receptors might 
be interesting for research on polytherapy. However, GABA agonistic drugs generally 
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exacerbate absence epileptic SWDs and therefore are not of any direct clinical 
relevance. Nevertheless, combining GABA agonistic drugs can be of theoretical 
relevance. Therefore, in this study GABA agonistic drugs were tested, in order to 
investigate the possible interaction effects of targeting both GABAA and GABAB 
receptors.
 Endogenous GABA concentrations can be increased by use of vigabatrin, an 
irreversible GABA transaminase inhibitor (Hammond and Wilder, 1985). By increasing 
endogenous GABA concentrations both the GABAA and GABAB neurotransmission is 
favoured. GABAB neurotransmission can be enhanced by the selective GABAB agonist 
R-baclofen (Bowery et al., 2002). Then, the combination of vigabatrin and R-baclofen 
is expected to tip the balance between GABAA and GABAB more towards GABAB.  
 Vigabatrin has been shown to increase the SWD activity in rats (Vergnes et 
al., 1984; Marescaux et al., 1992a, Bouwman et al., 2003b, Bouwman et al., 2003c). 
Furthermore, vigabatrin was shown to decrease the peak frequency of the SWDs 
(Bouwman et al., 2003b; Bouwman et al., 2003c). Baclofen has also been shown 
to increase the SWD activity in rats (Vergnes et al., 1984; Marescaux et al., 1992a). 
Interestingly, Destexhe (1999) suggests that especially GABAB neurotransmission 
determines the peak frequency of the SWDs, as long as there is enough GABAA 
neurotransmission to sustain the SWDs.
 In the present study the effects on the SWD incidence, average SWD duration, 
and on the SWD peak frequency, of several doses of vigabatrin and R-baclofen 
monotherapy and those of the combination of these drugs were measured in WAG/Rij 
rats. Where applicable the results are analysed using the isobolic method (Greco et 
al., 1995).
4.2. Materials and methods
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
4.2.1. Drugs
 Vigabatrin (Yamanouchi Pharma B.V., The Netherlands) and R-baclofen 
(Sigma-Aldrich Chemie Gmbh, Germany) were dissolved in saline (0.9%). Saline 
was used as the control for vigabatrin, R-baclofen and polytherapy treatment. Both 
drugs were administered intraperitoneally (i.p.), vigabatrin in a volume of 12.5 ml/kg 
and R-baclofen in a volume of 1.0 ml/kg. The volume differed in order to avoid effects 
of great osmolarity differences (Bouwman et al., 2003a). For vigabatrin the following 
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doses were used: 0 (saline), 65, 98, 148, 222, 333 or 500 mg/kg. The R-baclofen 
treatment consisted of the doses: 0 (saline), 0.65, 0.98, 1.48, 2.22, 3.33 or 5 mg/kg. 
For the polytherapy, the following combinations (vigabatrin/R-baclofen) were used: 
0/0, 65/0.65, 98/0.98, 148/1.48, 222/2.22 or 333/3.33 mg/kg (dose ratio= 100:1). 
4.2.2. Animals and experimental conditions
 Experiments were performed in 49, 9-months-old male WAG/Rij rats with an 
average weight of 318 g (S.E.=14 g). The rats were maintained on a reversed 12-h 
light-dark cycle with lights on at 20.00 h. The rats had ad libitum access to food and 
water.
 Each dose or combination was tested in 9 animals; a total of 162 observations 
were made. To limit the number of animals needed, each rat participated in up to four 
experimental sessions (4 treatments) with at least a 7 day interval between each 
session. Rats were semi-randomly assigned to up to four treatments, in a way that 
none of the rats received only control or high dose treatments. The selected treatments 
per rat were randomised over the four sessions. Experimental sessions were 
performed between 9.00 and 16.15 h. The experiment was performed on 41 separate 
experimental days, testing 4 rats per day. For the experimental design see table 1. 
Per experimental day, each rat received 2 injections: at 9.00 h saline (12.5 ml/kg) or 
vigabatrin and at 15.00 h saline (1.0 ml/kg) or R-baclofen. 
Table 1. The experimental schedule.
9.00 h injection 15.00 h injection Observed period (15.15–15.45 h)
Saline  Saline Control data
Vigabatrin Saline Vigabatrin monotherapy data
Saline R-baclofen R-baclofen monotherapy data
Vigabatrin R-baclofen Polytherapy data
  
4.2.3 Surgery and EEG recording
 Isoﬂurane anaesthesia was used during the implantation of a tripolar EEG 
electrode (Plastics One MS-332/2-A) on the cortical surface: one electrode on the 
frontal region (coordinates with skull surface ﬂat and bregma zero-zero: A2.0 L3.5) 
and a second one in the parietal region (A-6.0 L4.0) (Paxinos and Watson, 1997). 
The reference electrode was placed over the cerebellum. The rats were allowed to 
recover from surgery for at least 14 days before experimentation began. The rats 
were habituated to the experimental setting during 30 min per day on two successive 
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days before experimentation. On experimental days, 4 rats were placed in separate 
recording cages (19x19x40 cm) and connected with leads through swivels to an 
ampliﬁer and a computer-based data acquisition system (Dataq Instruments, OH, 
USA). The EEG signals in a bandwidth between 1 and 100 Hz, were sampled with a 
frequency of 512 Hz.
 The EEG of the rats was recorded continuously for a 30-min period, beginning 
15 minutes after the injection at 15.00 h. This period (6 h post vigabatrin injection) 
was chosen since GABA transaminase levels reach a minimum and GABA levels are 
maximally increased 4 h after vigabatrin injection, and these levels are maintained for 
24 h (Hammond and Wilder, 1985). Ofﬂine, the incidence and average duration of the 
spike and wave discharge activity, for the observed 30-min period, was determined 
by visual inspection based on the criteria for standard spike and wave discharges 
as proposed by Van Luijtelaar and Coenen (1986). The SWD peak frequency was 
determined using a Fast Fourier Transform procedure in Brain Vision Analyzer version 
1.04 (Brain Products GmbH, Germany) with a window of 2 s, starting at the beginning 
of the SWD. 
4.2.4. Statistics
 The data of the SWD incidence, average SWD duration and the SWD peak 
frequency were analysed, per variable, using univariate analyses of variance in SPSS 
version 11.5 for Windows (SPSS Inc., Chicago, Illinois USA) with dose as a between 
factor. Followed by Bonferroni’s multiple comparison when appropriate (α=0.05).
 To describe the dose-response relationship the sigmoid Emax model was ﬁtted 
to the data, using Graphpad Prism 4.02 for Windows (GraphPad Software, San Diego, 
California USA). Since most of the here presented data sets do not have measured 
data points in the full range of the curve, any interpretation of the Emax is hazardous. 
Therefore, effect points within the measured range were chosen. When the obtained 
curve ﬁts well on the data, these EDs are practically independent of the Emax. The 
following effect points were used; the ED(3x baseline), the ED(4xbaseline), the ED(5xbaseline), 
ED(0.5Hz decrease), ED(1Hz decrease) or the ED(1.5Hz decrease) were estimated, when appropriate. 
The ED(3x baseline), the ED(4x baseline) and ED(5xbaseline) were deﬁned as the dose necessary 
to obtain three, four or ﬁve times the baseline value respectively. The ED(0.5Hz decrease), 
ED(1Hz decrease) and the ED(1.5Hz decrease) were deﬁned as the dose necessary to obtain 0.5 
Hz, 1 Hz and 1.5 Hz decrease of the baseline frequency respectively. 
 When equal directed effect curves were obtained, the type of interaction 
between the drugs was analysed using the isobolic method (Greco et al., 1995); 
visually by plotting the estimated doses, needed to reach the chosen effect points, 
on an isobologram and numerically by comparing the drug load, needed to reach the 
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chosen effect point, of the observed polytherapy with the drug load of the theoretical 
additive combination.
 The drug load, deﬁned as             +           , was determined. gvg is the dose 
of vigabatrin in the polytherapy, GVG is the dose of vigabatrin in the monotherapy, 
bac is the dose of R-baclofen in the polytherapy, BAC is the dose of R-baclofen in 
the monotherapy, needed to reach the chosen effect point (Berenbaum, 1989). If 
an estimated drug load =1 then the drug effects are purely additive (no interaction). 
If the drug load <1 then there is supra-additivity (synergy). If the drug load >1 then 
there is subadditivity (antagonism) (Greco et al., 1995). T-tests were performed to test 
for differences between the theoretically additive and the experimental polytherapy 
combination (Motulsky, 1995).
4.3. Results
4.3.1. Effects on the SWD incidence
 There was a signiﬁcant effect of vigabatrin on the SWD incidence 
(F(6,56)=4.22; P=0.001). Posthoc analyses showed a signiﬁcant increase in the 
SWD incidence after 500 mg/kg compared to control (P<0.05). To describe the dose-
response relationship a sigmoid Emax model was ﬁtted through the data (see ﬁgure 1 
and table 2).
 There was a signiﬁcant effect of R-baclofen on the SWD incidence 
(F(6,56)=15.97; P<0.001). Posthoc analyses showed a signiﬁcant increase in the SWD 
incidence after 2.22 mg/kg (P<0.001), 3.33 mg/kg (P<0.001) and 5 mg/kg (P<0.001) 
as compared to control. To describe the dose-response relationship a sigmoid Emax 
model was ﬁtted through the data (see ﬁgure 1 and table 2).
 There was a signiﬁcant effect of polytherapy on the SWD incidence 
(F(5,48)=4.31; P=0.003). Posthoc analyses showed a signiﬁcant increase in the SWD 
incidence after 222/2.22 mg/kg (P<0.05) and 333/3.33 mg/kg (P<0.01) as compared 
to control. To describe the dose-response relationship a sigmoid Emax model was ﬁtted 
through the data (see ﬁgure 1 and table 2).
 gvg        bac
GVG     BAC
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 Figure 1. The means with the standard errors of the SWD incidence per dose of vigabatrin, R-baclofen and their 
 combination. Signiﬁcances compared to the control are indicated by asterisks.
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Table 2.  Isobolic analysis on the SWD incidence.
Vigabatrin
(GVG)
R-baclofen 
(BAC)
Theoretical 
additive
(GVG/BAC)
Experimental
combination
(GVG/BAC)
SWD
incidence
Emax
a
95% CIs
Bottom/Control 
value b
Hill c
95% CIs
66.5
57.1 - 75.9
9.56
7.41
2.54 - 12.3
66.5
57.1 - 75.9
9.56
3.72
2.55 - 4.89
66.5
57.1 - 75.9
9.56
0.75*
0.50 - 1.01
ED(3x baseline)
c (mg/kg)
95% CIs (mg/kg)
Drug load
95% CIs
265
231 - 305
1.0
0.87 - 1.15
1.32
1.20 - 1.45
1.0
0.91 - 1.1
87.9/0.88
76.4 - 101/
0.80 - 0.97
1.0
0.90 - 1.12
62.8/0.63
44.6 - 88.5/
0.45 - 0.89
0.71
0.51 - 1.01
ED(4x baseline)
c (mg/kg)
95% CIs (mg/kg)
 
Drug load
95% CIs
292 
 
261 - 327 
1.0 
0.89 - 1.12
1.59 
 
1.46 - 1.73 
1.0 
0.92 - 1.09
103/1.03 
91.9 - 115/ 
0.95 - 1.12 
1.0 
0.91 - 1.10
159/1.59 
132 - 192/ 
1.32 - 1.92 
1.54 * 
1.28 - 1.87
ED(5x baseline)
c (mg/kg)
95% CIs (mg/kg)
 
Drug load
95% CIs
321 
 
286 - 359 
1.0 
0.89 - 1.12
1.92 
 
1.73 - 2.12 
1.0 
0.90 - 1.10
120/1.20 
107 - 134/ 
1.08 - 1.33 
1.0 
0.90 - 1.11
403/4.03 
275 - 590/ 
2.75 - 5.90 
3.35 * 
2.29 - 4.92
 
The curve ﬁt parameters and the corresponding 95% conﬁdence intervals for the vigabatrin and R-baclofen mono-
therapies, the theoretical additive combination and the experimental combination. a indicating ﬁtted parameters, 
with a shared value for all treatments, b indicating ﬁxed parameters, c indicating ﬁtted parameters, separately ﬁtted 
for each treatment, and * indicating important deviations from the other values on the same parameter.
4.3.1.1. Isobolic analysis of the SWD incidence
 The chosen effect points for the isobolic analysis of the effects of the 
monotherapy and polytherapy treatments on the SWD incidence were the 
ED(3xbaseline), ED(4xbaseline) and ED(5xbaseline). Both ﬁgure 2 and table 2 show the ED(3xbaseline), 
ED(4xbaseline) and ED(5xbaseline) with the 95% CIs of vigabatrin, R-baclofen and their 
experimental combination for increasing the SWD incidence. Furthermore, they 
show the theoretical additive combination and the 95% CIs needed to obtain these 
ED values. The normalised ED(3xbaseline) (t(12)=2.05; P=0.063), i.e. drug load, for the 
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experimental combination is not signiﬁcantly different from that of the theoretical 
additive combination. The normalised ED(4xbaseline) (t(12)=3.47; P=0.005) and ED(5xbaseline) 
(t(12)=3.50; P=0.0044), i.e. drug load, for the experimental combination are signiﬁcantly 
higher than that of the theoretical additive combination. Thus, there was an infra-additive 
interaction between vigabatrin and R-baclofen on this variable for the effects of 4 and 
5 times the baseline, whereas for the effect of 3 times baseline the interaction was not 
signiﬁcantly different from additivity.
 
Figure 2. The isoboles of the ED(3xbaseline), ED(4xbaseline) and ED(5xbaseline) on the SWD incidence for the combination of 
 vigabatrin and R-baclofen, showing the theoretical additive combination and the experimental 
 combination with the 95% conﬁdence intervals.
4.3.2. Effects on the average SWD duration
 There was no signiﬁcant effect of vigabatrin on the average SWD duration (see 
ﬁgure 3). There was a signiﬁcant effect of R-baclofen on the average SWD duration 
(F(6,56)=2.494; P=0.033). To describe the dose-response relationship a sigmoid Emax 
model was ﬁtted through the data (see ﬁgure 3). There was no signiﬁcant effect of the 
polytherapy on the average SWD duration (see ﬁgure 3).
 Since the three treatments differed in their effect, i.e. two of the treatments 
were shown to have no signiﬁcant effect the isobolic analysis of the interaction could 
not be performed.
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Figure 3. The means with the standard errors of the average SWD duration per dose of vigabatrin, R-baclofen 
 and their combination.
4.3.3. Effects on the SWD peak frequency
 There was a signiﬁcant effect of vigabatrin on the SWD peak frequency 
(F(6,56)=55.46; P<0.001). Posthoc analyses showed a signiﬁcant decrease in the 333 
mg/kg (P<0.001) and the 500 mg/kg group (P<0.001) compared to control. To describe 
the dose-response relationship a sigmoid Emax model was ﬁtted through the data (see 
ﬁgure 4 and table 3).
There was a signiﬁcant effect of R-baclofen on the SWD peak frequency 
(F(6,56)=13.41; P<0.001). Posthoc analyses showed a signiﬁcant decrease in the 
SWD peak frequency in the 3.33 mg/kg (P<0.01) and the 5 mg/kg group (P<0.001) 
compared to control. To describe the dose-response relationship a sigmoid Emax model 
was ﬁtted through the data (see ﬁgure 4 and table 3).
There was a signiﬁcant effect of polytherapy on the SWD peak frequency 
(F(5,47)=22.18; P<0.001). Posthoc analyses showed a signiﬁcant decrease in the 
222/2.22 mg/kg (P<0.01) and the 333/3.33 mg/kg group (P<0.001) compared to 
control. To describe the dose-response relationship a sigmoid Emax model was ﬁtted 
through the data (see ﬁgure 4 and table 3).
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Figure 4. The means with the standard errors of the SWD peak frequency per dose of vigabatrin, R-baclofen and 
 their combination. Signiﬁcances compared to the control are indicated by asterisks.
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Table 3. Isobolic analysis on the SWD peak frequency.
Vigabatrin
(GVG)
R-baclofen 
(BAC)
Theoretical 
additive
(GVG/BAC)
Experimental
combination
(GVG/BAC)
SWD 
peak
frequency
Top/Control valueb
Emax
a
95% CIs
Hill c
95% CIs
8.35 
5.53 
4.81 - 6.26 
-4.98 
-7.01 - -2.94
8.35 
5.53 
4.81 - 6.26 
-1.76 
-2.12 - -1.40
8.35 
5.53 
4.81 - 6.26 
-2.31 
-3.12 - -1.52
ED(0.5 Hz decrease)
c 
(mg/kg)
95% CIs (mg/kg)
 
Drug load
95% CIs
 
207 
 
183 - 234 
1.0 
0.89 - 1.13
 
2.07 
 
1.65 - 2.62 
1.0 
0.79 - 1.26
 
104/1.04 
91.7 - 117/ 
0.82 - 1.31 
1.0 
0.84 - 1.20
 
119/1.19 
92.7 - 152 
0.93 - 1.52 
1.14 
0.89 - 1.46
ED(1 Hz decrease)
c 
(mg/kg)
95% CIs (mg/kg)
 
Drug load
95% CIs
 
250 
 
230 - 272 
1.0 
0.92 - 1.09
 
3.53 
 
3.04 - 4.10 
1.0 
0.86 - 1.16
 
146/1.46 
135 - 159/ 
1.26 - 1.70 
1.0 
0.90 - 1.12
 
178/1.78 
153 - 207/ 
1.53 - 2.07 
1.21 
1.05 - 1.41
ED(1.5 Hz decrease)
c 
(mg/kg)
95% CIs (mg/kg)
 
Drug load
95% CIs
 
289 
269 - 311 
1.0 
0.93 - 1.08
 
5.35 
 
4.30 - 6.65 
1.0 
0.80 - 1.24
 
188/1.88 
174 - 202/ 
1.51 - 2.33 
1.0 
0.88 - 1.14
 
244/2.44 
210 - 282/ 
2.10 - 2.82 
1.30* 
1.12 - 1.51
The curve ﬁt parameters and the corresponding 95% conﬁdence intervals for the vigabatrin and R-baclofen 
monotherapies, the theoretical additive combination and the experimental combination. a indicating ﬁtted 
parameters, with a shared value for all treatments, b indicating ﬁxed parameters, c indicating ﬁtted parameters, 
separately ﬁtted for each treatment, and * indicating important deviations from the other values on the same 
parameter.
4.3.4.1. Isobolic analysis of the SWD peak frequency
 The chosen effect points for the isobolic analyses of the effects of the 
monotherapy and polytherapy treatments on the SWD frequency were the ED(0.5Hz decrease), 
ED(1Hz decrease) and the ED(1.5Hz decrease). Both ﬁgure 5 and table 3 show the ED(0.5Hz decrease), 
ED(1Hz decrease) and the ED(1.5Hz decrease) with the 95% CIs of vigabatrin, R-baclofen and 
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their experimental combination for decreasing the SWD peak frequency. Furthermore, 
they show the theoretical additive combination and the 95% CIs needed to obtain 
these ED values. The normalised ED(0.5Hz decrease) (t(12)=0.842; P=0.42) and the ED(1Hz 
decrease) (t(12)=1.958; P=0.074), i.e. drug load, for the experimental combination are 
not signiﬁcantly different from that of the theoretical additive combination, whereas the 
normalised ED(1.5Hz decrease)  (t(12)=2.546; P=0.026) is signiﬁcantly higher than that of 
the theoretical additive combination. Thus, there was an additive interaction between 
vigabatrin and R-baclofen on this variable for the effect range up to 1 Hz decrease 
as compared to control, whereas for the effect of 1.5 Hz decrease there was an infra-
additive interaction between the drugs. 
 
Figure 5. The isoboles of the ED(0.5Hz decrease), ED(1Hz decrease) and the ED(1.5Hz decrease) on the SWD peak frequency for the 
  combination of vigabatrin and R-baclofen, showing the theoretical additive combination and the 
 experimental combination with the 95% conﬁdence intervals.
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4.4. Discussion
 We investigated the effects of the interaction between vigabatrin and R-
baclofen on SWDs in the absence epileptic WAG/Rij rat. Vigabatrin, R-baclofen and 
their combination dose dependently increased the SWD incidence, whereas only 
R-baclofen increased the average SWD duration. Furthermore, all treatments dose 
dependently decreased the SWD peak frequency.
 The increased SWD incidence after vigabatrin agrees with our earlier ﬁndings 
(Bouwman et al., 2003b; Bouwman et al., 2003c) and with ﬁndings of Vergnes et al. 
(1984) and Marescaux et al. (1992b). The increased SWD incidence after R-baclofen 
agrees with ﬁndings of Vergnes et al. (1984) and Marescaux et al. (1992a).
 Since on the SWD incidence similarly directed curves of the treatments were 
obtained, the isobolic analysis could be performed. This isobolic analysis showed that 
there was an infra-additive interaction between vigabatrin and R-baclofen on the SWD 
incidence for the effects of 4 and 5 times the baseline, whereas for the effect of 3 times 
baseline there was an additive interaction. These data suggest that a combination of 
a GABA transaminase inhibitor and a GABAB agonist might have an equal or lower 
SWD activity increasing potential than would be expected based on their SWD activity 
increasing potential as monotherapies, dependent of the effect point tested.
 Interestingly, the Hill parameter of the polytherapy combination on the SWD 
incidence differed from that of the monotherapies. The ﬂuctuating nature of the 
polytherapy interaction, being either infra-additive or additive, is due to the deviant 
Hill value (as compared to the monotherapies) of the polytherapy combination. 
Unfortunately, the underlying reason for the deviant Hill value of the polytherapy 
combination is unknown. Possibly, when both drugs are administered complex 
interactions occur. Indeed, when values are determined in complex in vivo systems, 
where factors such as differences in metabolism or in access to binding sites may 
affect the shape of the dose-response curve, the sigmoidicities are not necessarily 
equal (Berenbaum, 1989). Moreover, for the measurement of the combination we 
added baclofen six hours after the injection of vigabatrin. In these six hours the system 
might have adapted to the increased GABA concentrations, which might underlie the 
change in shape of the dose response curve of the polytherapy combination. These 
considerations give rise to a difﬁculty in interpretation of the results, for which no 
solution has been found to date. Therefore, models are needed in order to obtain an 
applicable solution to this problem (Van Rijn et al., 1999; Suffczynski et al., 2004; Van 
Rijn and Willems-van Bree, 2004). At present, the generalisation to other doses or 
effects can not be made. Therefore, these results can only be interpreted within the 
limitation of the corresponding effect ranges.
 The decreased SWD peak frequency after vigabatrin agrees with our earlier 
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ﬁndings (Bouwman et al., 2003b; Bouwman et al., 2003c). Furthermore, the decreased 
SWD peak frequency after vigabatrin, R-baclofen and their combination agrees with 
suggestions of Destexhe (1999) that the GABAB neurotransmission determines the 
peak frequency of the SWDs, as long as there is sufﬁcient GABAA neurotransmission 
to sustain the SWDs. Indeed, to our knowledge, no GABAA agonists are shown to 
decrease the peak frequency of SWDs, therefore the effect of vigabatrin is likely to 
be due to its increasing effect on the GABAB neurotransmission. Furthermore, the 
fact that the SWD peak frequency was only signiﬁcantly decreased by relatively high 
doses of R-baclofen, vigabatrin and their combination supports the ﬁnding that GABAB-
mediated inhibitory postsynaptic potentials require strong or sustained stimulation 
(Kim et al., 1997).
 Since on the SWD peak frequency similarly directed curves were obtained, 
the isobolic analysis could be performed. This isobolic analysis showed that vigabatrin 
and R-baclofen combined in a additive way on the SWD peak frequency in the effect 
range up to 1 Hz decrease, whereas for the effect of 1.5 Hz decrease there was an 
infra-additive interaction between the drugs. These data suggest that a combination 
of a GABA transaminase inhibitor and a GABAB agonist might have a lower SWD 
peak frequency decreasing potential than would be expected based on their as 
monotherapies, for a limited effect range. However, even though there was only a 
small difference between the Hill values of the monotherapies and the polytherapy 
combination, we can not exclude a possible effect of differing Hill values as was 
discussed earlier.    
 In conclusion, the interaction between vigabatrin and R-baclofen on the SWDs 
was shown to be either infra-additive or additive, dependent on the variable and effect 
points under investigation. However, in the present study a possible pharmacokinetic 
interaction between the two drugs was not investigated. A pharmacokinetic 
interaction might be a confounding factor underlying the obtained results. Therefore, 
generalisation towards clinical practice might be premature. Nevertheless, the variable 
and effect point dependent interaction between vigabatrin and R-baclofen, being either 
infra-additive or additive, suggests an interesting role for the interplay between GABAA 
and GABAB neurotransmission in the control and genesis of SWDs.
5
The effects of vigabatrin on 
absence epileptic spike and wave 
discharges in WAG/Rij rats
Bouwman B.M., Maris E., Suffczynski P., van den Broek P.L.C., Midzyanovskaya I.S. and 
van Rijn C.M. (submitted).
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Abstract
 The effects of vigabatrin, which increases GABA concentrations by 
inhibiting GABA transaminase, on spike and wave discharges (SWDs) in the 
electroencephalogram of WAG/Rij rats were studied. Vigabatrin increased the 
incidence and decreased the peak frequency of the SWDs from the 3rd hour after 
injection onwards, whereas the duration of the SWDs was increased already in the 1st 
hour after injection. These results further suggest that vigabatrin itself might be a direct 
GABAA agonist. Also, vigabatrin changed the course of the hazard rates of the SWD 
durations, suggesting besides a quantitative, also a qualitative GABAergic role in the 
mechanism(s) underlying the stopping of an ongoing SWD.
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5.1. Introduction
 Absence or “petit mal” seizures, also called “absences” are stereotyped 
generalised seizures with a highly characteristic electroencephalographic and 
behavioural pattern. The absence epileptic human electroencephalogram (EEG) as 
well as that of animal models of absence epilepsy are characterised by generalised 
spike and wave discharges (SWDs).
 The WAG/Rij rat, an inbred strain of rats, is recognised as an animal model 
of human absence epilepsy (van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 2003). Similar to the case of human absence epilepsy, mild behavioural 
concomitants such as accelerated breathing, twitching of the vibrissae and tiny head 
jerks, are visible during the presence of a SWD in the WAG/Rij rat (van Luijtelaar and 
Coenen, 1986; Coenen and van Luijtelaar, 2003).
 Despite extensive research, using valuable tools like the WAG/Rij rat model 
for human absence epilepsy (van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 2003), little is known about the exact mechanism(s) underlying absence 
epilepsy. For the development of new antiepileptic drugs, information about these 
underlying mechanisms is essential. By means of observing the effects of alterations 
in the neurotransmitter systems on various parameters of the SWDs, as can be 
obtained by pharmacological manipulations, more can be learned about the underlying 
mechanisms of absence epilepsy.
 Gamma-aminobutyric acid (GABA) is generally believed to be implicated in 
the occurrence and control of SWDs (Crunelli and Leresche, 2002). The GABAergic 
neurotransmission system contains two major receptor types, the GABAA and GABAB 
receptors. The GABAA receptor is an ionotropic receptor with a chloride channel, 
whereas the GABAB receptor is a metabotropic receptor coupled to calcium and 
potassium channels (Bowery et al., 2002). Both GABAA and GABAB receptors are 
activated by their natural agonist GABA. The maximal conductance activated by 
GABAB receptors is much smaller than that activated by GABAA receptors (Sodickson 
and Bean, 1996). Indeed, GABAB-mediated inhibitory postsynaptic potentials require 
stronger or more sustained stimulation than GABAA-mediated responses do (Kim et 
al., 1997). Thus, small increases in GABA concentrations do not necessarily result in in 
vivo effects dominated by GABAB-mediated responses.
 It has been shown that both GABAA- and GABAB-ergic drugs modulate the 
SWDs (Vergnes et al., 1984; Peeters et al., 1989; Duysens et al., 1991; Marescaux et 
al., 1992b; Budziszewska et al., 1999; Kaminski et al., 2001; Bouwman et al., 2003b; 
Bouwman et al., 2004). Interestingly, it has been suggested that not the absolute level 
of GABA but more speciﬁcally the balance between GABAA and GABAB conductances 
is essential for the control of SWDs (Destexhe, 1999; Destexhe and Sejnowski, 
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2003). Therefore, targeting both GABAA and GABAB receptors might be interesting for 
research on mechanisms underlying absence epilepsy.
 In vivo, the balance between GABAA and GABAB conductances can be easily 
altered by pharmacological manipulations. Endogenous GABA concentrations can 
be increased by use of vigabatrin. Vigabatrin is an antiepileptic drug that irreversibly 
inhibits GABA transaminase (Hammond and Wilder, 1985), and thus increases GABA 
concentrations. By increasing endogenous GABA concentrations both the GABAA and 
GABAB neurotransmission is favoured. Since the efﬁcacy of GABA for the GABAA and 
GABAB receptors is different, and the regional distribution of these receptors differs 
throughout the brain (Chu et al., 1990; Gottesmann, 2002), the balance between 
GABAA and GABAB conductances can be altered by vigabatrin administration.
 The effects of vigabatrin on SWDs might provide further knowledge on the 
underlying mechanisms involved in the control of the absence epileptic SWDs. 
Therefore, in the present study, the effects of vigabatrin on SWDs in the EEG of WAG/
Rij rats were studied. Since the rise of GABA concentration as a result of vigabatrin 
injection has a slow onset (Hammond and Wilder, 1985; Valdizán et al., 1999; Tong et 
al., 2000), the effects on SWDs were measured up to the seventh hour after injection.
5.2. Materials and Methods
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
 Male WAG/Rij rats (n=16), 1-year-old, with a mean body weight of 331 g 
(S.E.= 4 g), were used. The rats were maintained on a reversed 12-h light-dark 
cycle with lights on at 20.00 h. The rats had ad libitum access to food and water. 
Isoﬂurane anaesthesia was used during the implantation of a tripolar EEG electrode 
(Plastics One MS-332/2-A) on the cortical surface: one electrode on the frontal region 
(coordinates with skull surface ﬂat and bregma zero-zero: A2.0 L3.5) and a second 
one in the parietal region (A-6.0 L4.0). The reference electrode was placed over 
the cerebellum. The rats were allowed to recover from surgery for 28 days before 
experimentation began.
 The rats were habituated to the experimental setting during 30 min per day on 
two successive days before experimentation. Experimental sessions were performed 
between 9.00 and 16.00 h. At 9.00 h the rats received an i.p. injection containing either 
saline (0.9%) or 500 mg/kg of vigabatrin (Yamanouchi Pharma B.V., The Netherlands) 
dissolved in saline (0.9%) in a volume of 2ml/kg. On experimental days, 4 rats 
were placed in separate recording cages (19x19x40 cm) and connected with leads 
through swivels to an ampliﬁer and a computer-based data acquisition system (Dataq 
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Instruments, OH, USA). The EEG signals in a bandwidth between 0.1 and 100 Hz, 
were sampled with a frequency of 512 Hz.
 Ofﬂine, the SWDs were detected by visual inspection based on the criteria 
for standard spike and wave discharges as proposed by van Luijtelaar and Coenen 
(1986). For the recordings of the 7th hour, only data of 5 of the 8 rats in the vigabatrin 
group could be analysed, since the SWDs during this period in the other 3 rats could 
not be distinguished from background EEG. SWD incidence, duration and SWD peak 
frequency were determined per block of one hour. The SWD peak frequency was 
determined from the frequency spectrum of the ﬁrst 2 seconds of each SWD. The 
frequency spectrum was obtained by tapering the signal with a Hanning window and 
subsequently applying a Fast Fourier Transform.
 Statistical analyses on the SWD incidence, duration and peak frequency 
were performed, using a repeated measures Analysis of Variance for each dependent 
variable, treating time as a within subjects (rats) factor and treatment as a between 
subjects (rats) factor (α=0.05). To describe the Time*Treatment interactions, posthoc, 
independent samples T-tests were performed in SPSS version 11.5 for Windows 
(SPSS Inc., Chicago, Illinois USA). If the within sample variances were signiﬁcantly 
different (as assessed by means of Levene’s procedure), the degrees of freedom for 
the T-tests were corrected according to Satterthwaite’s method (1946). To illustrate 
the course of the effects over time, appropriate curves or straight lines were ﬁtted to 
the data using GraphPad Prism 4.02 for Windows (GraphPad Software, San Diego, 
California USA).
 For every condition (six time intervals times two groups, vigabatrin and saline), 
we obtained histograms of SWD durations. These histograms were transformed into 
hazard rates by a modiﬁcation of the estimation algorithm of Müller and Wang (1994) 
(see Maris et al., in press, for details). The hazard rate of the SWD durations can be 
interpreted as the instantaneous probability of stopping the SWD as a function of time. 
The time course of this instantaneous stopping probability reveals information about 
the underlying SWD stopping mechanism (Maris et al., in press).
5.3. Results
 For the recordings of the 7th hour, only data of 5 of the 8 rats in the vigabatrin 
group could be analysed, since the SWDs during this period in these rats could not be 
distinguished from background EEG (and might even be considered as SWD-like). 
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5.3.1. Effects on SWD incidence
 Means and 95% conﬁdence intervals of the averaged number of SWDs per 
hour per rat per treatment are shown in ﬁgure 1 (upper panel). Statistical analyses 
showed a Time*Treatment interaction effect (F(6,9)=34.35; P<0.001). The posthoc 
T-tests showed an increase in the SWD incidence after vigabatrin as compared to the 
saline group in the 3rd (P<0.001), 4th (P<0.001), 5th (P<0.001), 6th (P<0.01) and the 7th 
hour (P<0.05). 
5.3.2. Effects on SWD duration
 Means and 95% conﬁdence intervals of the averaged duration of SWDs per 
hour per rat per treatment are shown in ﬁgure 1 (middle panel). Statistical analyses 
showed a Time*Treatment interaction effect (F(6,9)=3.724; P=0.038). The posthoc 
T-tests showed an increase in SWD duration after vigabatrin as compared to the saline 
group in the 1st (P<0.05), 2nd (P<0.01), 3rd (P<0.05), 4th (P<0.01), 5th (P<0.01) and the 
6th hour (P<0.05).
 
5.3.3. Effects on SWD peak frequency
 The averaged peak frequency per rat per hour per treatment was determined. 
The averaged peak frequency per hour per treatment is shown in ﬁgure 1 (lower 
panel). Statistical analyses showed a Time*Treatment interaction effect (F(6,9)=17.52; 
P<0.001). The posthoc T-tests showed a decrease in SWD peak frequency after 
vigabatrin as compared to the saline group in the 3rd (P<0.001), 4th (P<0.001), 5th 
(P<0.001), 6th (P<0.001) and the 7th hour (P<0.001).
5.3.4. Effects on hazard rates of the SWD durations
 The hazard rates per hour per treatment are shown in ﬁgure 2. In the saline 
group, the hazard rate of the SWD durations is increasing, independent of the time 
that has elapsed since the injection. In the vigabatrin group, the ﬁrst 3 hours after the 
injection show increasing hazard rates, very similar to the saline group. However, from 
the 4th hour after the injection until the end of the registration period (7 hours after the 
injection) the hazard rate decreases.
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Figure 1. Mean SWD incidence, duration and peak frequency as a function of time and treatment (n=8 rats) with 
 the corresponding standard errors. Asterisks indicate statistical signiﬁcances in the T-tests. To illustrate 
 the time course of the effects, appropriate curves or straight lines were ﬁtted to the data.
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Figure 2. The hazard rates as a function of the SWD duration, per treatment (columns) per hour post injection 
 (rows), with the corresponding 95% conﬁdence intervals (dotted lines). Plots are truncated at 95% of 
 the observed SWD durations.
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5.4. Discussion
 The objective of this study was to investigate the effects of vigabatrin on 
SWDs in the EEG of WAG/Rij rats. The incidence of the SWDs was signiﬁcantly 
increased after vigabatrin, from two hours post injection onwards, as compared to the 
saline condition. The SWD duration was increased after vigabatrin as compared to 
saline, already in the ﬁrst hour post injection. The peak frequency of the SWDs was 
decreased after vigabatrin, from two hours post injection onwards, as compared to 
the saline condition. The hazard rates of the SWD durations changed after vigabatrin, 
from an increasing trend, which was consistently observed in the saline group, to a 
decreasing trend, from the fourth hour onwards.
 The effect of vigabatrin on the SWD incidence and the peak frequency agrees 
with earlier ﬁndings in the WAG/Rij rat model (Bouwman et al., 2003b; Bouwman et al., 
2004). Vigabatrin also enhances the SWD incidence in GAERS, another well known 
model of absence epilepsy in rats (Vergnes et al., 1984; Marescaux et al., 1992b). 
Furthermore, the SWD incidence was shown to be increased after both GABAA and 
GABAB agonists (Vergnes et al., 1984; Peeters et al., 1989; Duysens et al., 1991; 
Marescaux et al., 1992b; Budziszewska et al., 1999).
 Interestingly, the decreased peak frequency after vigabatrin also agrees with 
simulated data based on alterations in GABAA and GABAB conductance (Destexhe, 
1999; Destexhe and Sejnowski, 2003). Thus, our in vivo data also support the 
proposed theory that fast and slow spike-and-wave oscillations are part of a continuum 
of oscillatory states, in which frequency and duration are determined by GABAA and 
GABAB conductances in thalamocortical relay cells (Destexhe, 1999; Destexhe and 
Sejnowski, 2003). Furthermore, the peak frequency of the SWDs might be mainly 
determined by favouring the balance between GABAA and GABAB conductances more 
towards GABAB neurotransmission (Destexhe, 1999; Destexhe and Sejnowski, 2003). 
Indeed, we only observed similar effects on the SWD peak frequency after drugs with 
GABAB agonistic properties (Bouwman et al., 2003b; Bouwman et al., submitted). 
 The hazard rate of the SWD durations reveals information about the underlying 
SWD stopping mechanism. In the saline group, the hazard rates of the SWD durations 
are increasing. This indicates that, in the saline group, the probability of the SWD 
stopping the next instant of time increases with time. This increasing probability can 
be considered as a manifestation of a brain mechanism that protects the animal 
from having ongoing seizures. In the vigabatrin group, four hours after vigabatrin 
administration, the hazard rates of the SWD durations become decreasing. This 
means that the probability of the SWD stopping the next instant of time decreases with 
time. It appears that, around that time, the brain loses its protective mechanism and 
even gets “addicted” to having seizures. The effect of vigabatrin on the hazard rates of 
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the SWD durations suggests GABAergic involvement in the mechanism(s) underlying 
the stopping of an ongoing SWD.
 It has been shown that the whole brain GABA concentration is maximally 
increased 2 to 4 hours after vigabatrin administration and is maintained for 24 hours 
(Hammond and Wilder, 1985; Valdizán et al., 1999; Tong et al., 2000). Interestingly, 
the time dependency of the effects on the SWD incidence, the SWD peak frequency 
and the hazard rates of the SWD durations, agrees with the time dependency of the 
enhancement of GABA concentrations after vigabatrin (Hammond and Wilder, 1985; 
Valdizán et al., 1999; Tong et al., 2000). This might suggest that the effects on these 
variables are due to the GABA concentration increasing effects of vigabatrin. 
 However, the duration of the SWDs is already increased in the ﬁrst hour 
after vigabatrin administration. This might suggest that the SWD duration variable 
is more sensitive for the effects of vigabatrin than the other variables. On the other 
hand, it might suggest that there is a direct effect of vigabatrin (besides its indirect 
effect as a GABA transaminase inhibitor). Indeed, there have been some suggestions 
of direct effects of vigabatrin on the GABAA receptor (Löscher, 1980; Suzuki et al., 
1991; Hanaya et al., 2002). However, it has been suggested that vigabatrin might 
be a GABAA antagonist (Suzuki et al., 1991), whereas others have suggested that 
vigabatrin might be a GABAA agonist (Löscher, 1980; Hanaya et al., 2002). Since 
GABAA agonists, and not GABAA antagonists, were shown to facilitate SWDs in the 
WAG/Rij rat (Peeters et al., 1989; Duysens et al., 1991; Budziszewska et al., 1999), 
the results on the SWD duration of the present study support the suggestion that 
vigabatrin itself might be a GABAA agonist.
 In conclusion, vigabatrin was shown to increase the SWD incidence and SWD 
duration, suggesting a quantitative GABAergic involvement in the mechanism(s) 
underlying the starting and stopping of an ongoing SWD. Furthermore, vigabatrin 
decreased the SWD peak frequency, suggesting an important role of GABA in the 
mechanism(s) underlying the peak frequency of the SWDs. Also, vigabatrin was 
shown to change the shape of the hazard rates of the SWD durations. This suggests 
that vigabatrin changes a qualitative aspect of the SWD stopping mechanism, and not 
just quantitative aspects such as the rate of increase/decrease of the hazard rate. The 
time dependency of the effects on the SWD incidence, peak frequency and the hazard 
rates of the SWD durations, agrees with the time dependency of the enhancement of 
GABA concentrations after vigabatrin. Interestingly, the results on the SWD duration 
of the present study support the suggestion that vigabatrin itself might be a GABAA 
agonist.
6
GABAergic mechanisms in absence 
epilepsy: A computational model 
of absence epilepsy simulating 
spike and wave discharges after 
vigabatrin in WAG/Rij rats
Bouwman B.M., Suffczynski P., Maris E., Lopes da Silva F.H. and van Rijn C.M. (in 
preparation)
Chapter 6
70
Abstract
 In this study, the effects of vigabatrin on spike and wave discharges (SWDs) 
were measured in WAG/Rij rats, an animal model of absence epilepsy. Vigabatrin was 
used to increase the GABAergic neurotransmission. These in vivo data were simulated 
by a computational model, in order to investigate possible mechanisms involved in the 
changes in SWDs after vigabatrin. The model parameter (representing GABA levels) 
changes needed to obtain model behaviour similar to the in vivo SWD data were 
linked to the mechanism of action of the drug. The results show that the computational 
model can simulate the obtained in vivo data, on the assumption that an increase of 
GABAergic neurotransmission due to application of vigabatrin is most pronounced at 
the level of the thalamic relay nuclei (TC cells). Furthermore, vigabatrin was shown to 
affect both the SWD starting and stopping mechanisms, as reﬂected by hazard rates. 
Based on these results, it is suggested that GABAergic neurotransmission in TC cells 
is actively involved in the SWD termination.
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6.1. Introduction
 Absence or “petit mal” seizures, also called “absences” are stereotyped 
generalised seizures with a highly characteristic electroencephalographic and 
behavioural pattern. The absence epileptic human electroencephalogram (EEG) as 
well as that of animal models of absence epilepsy are characterised by generalised 
spike and wave discharges (SWDs). It has been shown that both cortical and thalamic 
neurons are necessary to generate SWDs and that both GABAA and GABAB receptors 
are actively involved (Gloor et al., 1977; Hosford et al., 1992; Snead, 1992; von 
Krosigk et al., 1993; Puigcerver et al., 1996; Steriade and Contreras, 1998; Meeren 
et al., 2002). However, despite extensive research, the exact mechanisms underlying 
SWDs are still unclear. Interestingly, computational models can be used to provide 
understanding of the in vivo data, since these models are essentially simpliﬁed 
representations of the brain.
 To investigate mechanisms of SWD generation in rodent models of absence 
epilepsy, Destexhe (1999) developed a computational model for a network involving 
both thalamus and cortex, in which gamma-aminobutyric acid (GABA) and glutamate 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are 
involved. Destexhe (1999) showed with this computational model that SWDs with 
different peak frequencies can be obtained by the same thalamocortical mechanism, 
by varying the GABAergic receptor type (GABAA or GABAB) governing inhibition in 
the thalamic TC cells. Based on these results, Destexhe (1999) proposed that these 
SWDs with different peak frequencies are part of a continuum of oscillatory states. This 
suggestion agrees with the time dependent gradual decrease in the peak frequency of 
SWDs after vigabatrin in rats (Bouwman et al., 2003b; Bouwman et al., in preparation). 
Vigabatrin is a GABA transaminase inhibitor, thus increasing GABA concentrations. 
The resulting increased GABA concentration affects both GABAA and GABAB 
conductances in different intensities due to the different activation properties of these 
receptors (Sodickson and Bean, 1996; Kim et al., 1997). Therefore, the decreased 
peak frequency of the SWDs is likely to be the result of an alteration of the balance 
between GABAA and GABAB.
 Not only the within-SWD variables, such as duration and peak frequency, but 
also the between-SWD variables, such as incidence and distribution over time, are of 
vital importance in order to learn more about the mechanisms underlying the SWDs. 
Therefore, we developed a computational model that is able to simulate both the 
within- and the between-SWD variables (Suffczynski et al. 2004). This model involves 
a simpliﬁed network containing both thalamus and cortex, in which GABA and AMPA 
receptors and IT calcium currents are involved.  For a wide range of parameters the 
model is in a bistable regime where it may generate both “normal ongoing activity” and 
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paroxysmal “seizure-like” oscillations (SWDs) and spontaneous transitions between 
these two types of behaviour.
 Also, by investigating the effects of pharmacological manipulations on SWDs, 
more can be learned about the mechanisms and networks that underlie them. 
Interestingly, computational models can also be used to simulate obtained in vivo data 
(after pharmacological manipulations), and to predict which location in the simulated 
network is most responsible for the observed effects.
 Indeed, in the present study, the Suffczynski et al. (2004) model was used to 
simulate effects of vigabatrin on SWDs in vivo. The in vivo data were obtained after 
injection of several doses of vigabatrin in WAG/Rij rats. The WAG/Rij rat model is 
a well established animal model of absence epilepsy (Coenen et al., 1992). Similar 
to the absence epileptic human, the SWDs in the EEG of the WAG/Rij rat are often 
accompanied by vibrissal twitches (van Luijtelaar and Coenen, 1986). Therefore, the 
fraction of SWDs with vibrissal twitches was analysed, to validate that the analysed 
SWDs after vigabatrin are indeed SWDs, and have similar clinical manifestations. 
Vigabatrin was used to modulate the GABAergic neurotransmission in the rats. 
Since the rise in GABA concentration as a result of the GABA transaminase inhibitor 
vigabatrin (Hammond and Wilder, 1985) has a slow onset (Tong et al., 2000), the 
effects of vigabatrin on the SWDs were measured six hours after injection. 
 Liu et al. (1991) already showed that local applications of vigabatrin might 
affect the SWDs differently, depending on the site of application. Then, when 
vigabatrin is injected systemically, the question arises whether the effects are 
either homogeneous or heterogeneous throughout the brain, and in the case of a 
heterogeneous increase, which speciﬁc regions are mostly affected by vigabatrin. 
This allowed for an evaluation of the most likely mechanisms involved in the changes 
in SWD variables after vigabatrin. In order to investigate this question, the model 
parameter changes representing the changes of GABA levels, needed to obtain model 
behaviour similar to the in vivo SWD data, were linked to the mechanism of action of 
the drug.
6.2. Materials and methods
6.2.1. In vivo experiment
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
The presented data are part of a larger data set (also data after other drugs) and 
were obtained in two separate experiments with the same design. Male WAG/Rij rats 
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(n=75), 8 months old, with a mean body weight of 323 g (S.E.=1.7 g), were used. 
Animals were individually housed in Macrolon cages, and were maintained on a 
reversed 12-h light-dark cycle with lights on at 20.00 h. Food and water were available 
ad libitum. A permanent cortical tripolar electrode (Plastics One MS-332/2-A) was 
implanted under complete isoﬂurane anaesthesia, one electrode in the frontal region 
(coordinates with the skull surface ﬂat and bregma zero-zero: A 2.0, L 3.5), and the 
other in the parietal region (A –6.0, L 4.0) (Paxinos and Watson, 1997). The ground 
electrode was placed over the cerebellum. The electrodes were ﬁxed to the skull using 
two stainless-steel screws and dental acrylic. After the surgery, the animals were 
allowed to recover for at least 2 weeks.
 Rats were placed into transparent recording cages, connected to an EEG 
cable, and habituated to the experimental conditions on four separate days, each 
day during 1 h.  Experimental sessions were performed between 9:00 and 17:00 h 
on 65 separate days, 1-4 rats per day. At 9.00 h the rats were injected i.p. with saline 
(12.5 ml/kg) or one of the doses of vigabatrin: 65, 98, 148, 222, 333 or 500 mg/kg 
(12.5 ml/kg) (Yamanouchi Pharma B.V., The Netherlands). Each rat received the 
experimental conditions in a semi-random fashion, so that each dose of the drug 
conditions was measured in 15 rats. Each rat was used at least once but no more than 
3 times (resulting in 115 included measurements in total), with at least 8 days between 
experimental days. During 30 minutes at 14.30 h, the presence of vibrissal twitches 
of 5 to 8 rats per dose was scored online, by means of visual observations, for 15 
minutes per rat.
 The EEG in a bandwidth between 1 and 100 Hz, was digitalised with a sample 
frequency of 512 Hz, and stored for an off-line analysis using the Windaq system 
(DATAQ Instruments, OH, USA). The SWDs were marked after visual inspection based 
on the criteria for standard SWDs as proposed by van Luijtelaar and Coenen (1986).
 The fraction of SWDs with vibrissal twitches, the total duration and the peak 
frequency of the SWDs during 30 minutes at 14.30 h were off-line determined. The 
SWD peak frequency was analysed, using a Fast Fourier Transform procedure with 
a window of 2 seconds, starting at the beginning of the SWD (SWDs shorter than 
2 seconds were excluded for this analysis). Statistical analyses on the fraction of 
SWDs with vibrissal twitches and the SWD data per variable were performed using 
the ANOVA procedure in SPSS 11.5 for Windows (SPSS Inc., Chicago, Illinois USA). 
Posthoc analyses were performed using the Bonferroni correction. A signiﬁcance level 
of 0.05 was used.
 To describe the dose-response relationships, sigmoid Emax models were ﬁtted 
to the data in GraphPad Prism 4.02 for Windows (GraphPad Software, San Diego, 
California USA). Since most of the data sets presented here do not have data points in 
the full range of the curve, any interpretation of the Emax is hazardous. Therefore, effect 
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points within the measured range were chosen; the ED(4xbaseline) or the ED(1.5 Hz decrease) 
were estimated, when appropriate. The ED(4x baseline) was deﬁned as the dose necessary 
to obtain four times the baseline value. The ED(1.5 Hz decrease) was deﬁned as the dose 
necessary to obtain 1.5 Hz decrease of the baseline frequency. When the obtained 
curve ﬁts well on the data, these EDs are practically independent of the Emax.
 We obtained histograms of durations of inter-SWD intervals and SWD 
durations for the saline and 500 mg/kg of vigabatrin groups. These histograms 
were transformed into hazard rates by a modiﬁcation of the estimation algorithm of 
Müller and Wang (1994) (see Maris et al., in press, for details). The hazard rate of 
the durations of the inter-SWD intervals can be interpreted as the instantaneous 
probability that a SWD will start as a function of time. The time course of this 
instantaneous starting probability reveals information about the underlying SWD 
starting mechanism (see Maris et al., in press). Similarly, the hazard rate of the SWD 
durations can be interpreted as the instantaneous probability that the SWD will stop as 
a function of time. The time course of this instantaneous stopping probability reveals 
information about the underlying SWD stopping mechanism (see Maris et al. in press). 
6.2.2. Computational model
 The model of a thalamocortical network is an extended version of the lumped 
model initially proposed by Lopes da Silva et al. (1974). The latter general model 
of rhythmic activity was based on two interacting populations of neurons, namely 
excitatory cells of a main population that projected to the interneurons while the 
latter fed back on the main cells, inhibiting them with fast GABAA receptor mediated 
inhibitory postsynaptic potentials (IPSPs). Each population was described by the 
time courses of postsynaptic potentials and a sigmoid transfer function, which was 
used to simulate the conversion between the mean membrane potential of a neuronal 
population and the ﬁring rate (number of pulses per second (pps)) of the population. 
We made a number of extensions and added new features to the above described 
model. The present model is advanced with respect to its precursor in three main 
points (a detailed model description is given in Suffczynski et al. (2004)): (i) It consists 
of two loops, cortical and thalamic ones, that are mutually interconnected. (ii) The 
transformation between mean membrane potential and ﬁring rate in the thalamic 
populations takes into account the low-threshold IT calcium current that underlies burst 
ﬁring in the thalamic cells. (iii) In addition both fast GABAA and slow GABAB receptor 
mediated inhibitions are included. The schematic diagram of the model is shown in 
ﬁgure 1. 
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Figure 1. Schematic structure of connections in the thalamocortical network model consisting of cortical and
 thalamic modules. The cortical module consists of two interconnected populations of PY and IN 
 neurons. The thalamic module consists of two interconnected populations of the TC and RE neurons. 
 TC cells project to both the PY and IN cells, while PY cells project to both the TC and RE cells. The PY 
 population receives external cortical excitatory input, the TC population receives external sensory input 
 and the RE population receives external inhibitory input. Figure’s legend shows synaptic connection types. 
 The thalamic loop consists of a population of thalamocortical (TC) cells 
that project to a population of reticular thalamic (RE) cells. The latter inhibits TC 
population by way of GABAA and GABAB types of inhibition. The TC cells receive 
external excitatory input that represents sensory inputs from the ascending afferents 
while the RE population receives external inhibitory input. The latter represents the 
input from the neighbouring RE cells, since these are interconnected by mutual 
inhibitory synapses. The cortical circuit consists of a negative feedback loop formed 
by interacting populations of pyramidal cells (PY) and inhibitory interneurons (IN). 
Pyramidal cells, in addition to projecting to interneurons, send also excitatory 
connections to the thalamus both to the TC and RE populations. In turn, the TC cells 
excite both the pyramidal cells and interneurons. The PY population receives also 
external cortical input that stands for the glutamatergic input from other pyramidal 
cells, not included in the lump. All excitatory synaptic interactions are mediated by 
AMPA receptors. The output of the model, is the mean membrane potential of the 
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pyramidal cell population. We assume that the dynamics of this activity (e.g., dominant 
frequency) is reﬂected on the local ﬁeld potential recordings and EEG signals that 
have the same dynamical properties. However, in the present model we didn’t aim to 
simulate realistic ﬁeld potential waveforms. 
6.2.2.1. Different types of model behaviour
 The model may exhibit two qualitatively different types of behaviour, such as 
seen in the experimental animals. The output signal may display waxing and waning 
oscillations having a spectrum with a peak at approximately 11 Hz or a high amplitude 
“seizure-like” oscillation at a frequency around 9 Hz. We refer to the former behaviour 
as “normal on-going” activity while to the latter as SWD activity. For a broad range 
of parameters, the model is in a bistable regime where it may generate both normal 
and paroxysmal oscillations and spontaneous transitions between these two types of 
behaviour (see Suffczynski et al., 2004 for the details).
6.2.2.2. Simulation of vigabatrin treatment
 Vigabatrin is a GABA transaminase inhibitor and is supposed to increase 
GABA concentrations (Hammond and Wilder, 1985). Accordingly, we simulated the 
effect of vigabatrin administration by a change, relative to an arbitrary reference state, 
in output from GABAergic populations in the model. However it is not clear whether 
the vigabatrin action is homogenous within the brain or whether it affects some brain 
areas more than others. Therefore we considered four distinct targets of vigabatrin 
action: (i) both the cortex and thalamus, (ii) only cortex, (iii) only thalamus and (iv) 
only thalamocortical nucleus. These four possibilities were simulated respectively by 
an increase of output of GABAergic cells projecting to: (i) PY, TC and RE cells, (ii) PY 
cells, (iii) TC and RE cells and (iv) TC cells. For each change of GABA concentration 
at each target location, we simulated 24 hours of activity and detected paroxysmal and 
normal epochs as described in Suffczynski et al. (2004). To fully explore the effects 
of changing the GABA concentrations, the concentrations were both increased and 
decreased at each target location, such that the system’s behaviour varied from at 
least one paroxysmal event during 24 hours, to a state of continuous paroxysmal 
activity. We analysed simulated signals with respect to: incidence, average duration, 
total duration, and peak frequency of SWDs, and also hazard rates of SWD durations 
and inter SWD durations. 
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6.3. Results
6.3.1. Fraction of SWDs with vibrissal twitches
 Statistical analysis on the data of the fraction of SWDs with vibrissal twitches 
showed that there is no signiﬁcant effect of vigabatrin (F(6,35)=0.27; P>0.05). Overall, 
66 percent of the observed SWDs were accompanied by vibrissal twitches. 
6.3.2. Total duration of SWDs
 Figure 2 shows the total duration of the SWDs.
Rats: Statistical analysis shows that there is a signiﬁcant increase after vigabatrin 
(F(6,96)=5.77; P<0.001). The dose-response relationship was ﬁtted according to the 
sigmoid Emax model; ED(4xbaseline)= 324 mg/kg; S.E.= 32 mg/kg.
Model: An increase of GABA concentration in the whole network (i.e., equally in 
cortex and thalamus), the thalamus (i.e., equally in TC and RE populations) or only 
in cortex decreased total SWD duration. An increase of GABA concentration in the 
thalamocortical population increased the total duration of SWDs.
Figure 2. The total duration of the SWDs as a function of drug dose, 6 hours after injection (left). Signiﬁcances 
 compared to the control are indicated by asterisks. The total SWD duration, in four different 
 thalamocortical network situations, as a function of the relative GABA level change in percentage 
 around its reference value (R) from the model simulation of 24 hours of activity (right).
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6.3.3. Peak frequency of SWDs
 Figure 3 shows a typical SWD for the saline and the 500 mg/kg vigabatrin 
treated rats (upper panel), and the power spectra for these SWDs (lower panel), 6 
hours after injection. Figure 4 shows the peak-frequency of the SWDs.
Rats: Statistical analysis on the data of the peak frequency shows that there is a 
signiﬁcant decrease after vigabatrin (F(6,95)= 39.22; P<0.001). The dose-response 
relationship was ﬁtted according to the sigmoid Emax model; ED(1.5 Hz decrease)= 290 mg/kg; 
S.E.= 15 mg/kg. 
Model: An increase of GABA concentration in the whole network (i.e., both cortex and 
thalamus), cortex alone or in the thalamus alone increased or affected biphasically 
the peak frequency, while an increase of GABA concentration in the thalamocortical 
population monotonously decreased the peak frequency of the SWDs. 
 
Figure 3. A typical SWD 6 hours after injection for the saline and the 500 mg/kg vigabatrin group and the 
 corresponding power spectra.
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Figure 4. The SWD peak frequency as a function of drug dose, 6 hours after injection (left). Signiﬁcances 
 compared to the control are indicated by asterisks. The SWD peak frequency as a function of the 
 relative GABA level change in percentage around its reference value (R), in four different 
 thalamocortical network situations, from the model simulation of 24 hours of activity (right).
6.3.4. Distributions of the durations of the inter-SWD 
intervals
 Figure 5 shows the histograms of the durations of the inter-SWD intervals 
for the saline and 500 mg/kg of vigabatrin treated rats and the model. All of the three 
histograms show a maximum at their origin and decay as the length of the inter-
SWD interval increases. Additional information concerning the properties of these 
distributions can be obtained using hazard rates.
 
Figure 5. The histograms of the durations of the inter-SWD intervals, for the saline and the 500 mg/kg vigabatrin 
 treated rats, and the model using the reference parameters (truncated at 95% of the data).
Figure 6 (left panel) shows the hazard rate as a function of the durations of the inter-
SWD intervals for the saline and 500 mg/kg of vigabatrin treated rats and the model. 
In both the saline and vigabatrin treated rats, the hazard rates of the durations of 
the inter-SWD intervals are decreasing. However, overall, the absolute value of the 
hazard rate is higher in the vigabatrin group. In the model data, the hazard rates of the 
durations of the inter-SWD intervals tended to be horizontal irrespective of location and 
degree of GABA concentration manipulation.
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Figure 6. The hazard rates of the durations of the inter-SWD intervals (left) and the SWD durations (right), for the 
 saline and the 500 mg/kg vigabatrin treated rats, and the model using the reference parameters 
 (truncated at 95% of the data).
6.3.5. Distributions of the SWD durations
Figure 7 shows the histograms of the SWD durations for the saline and 500 mg/kg of 
vigabatrin treated rats and the model. For the saline treated rats, there is a more or 
less symmetric distribution centred on the dominant SWD duration. In the vigabatrin 
group, the histogram is asymmetric with a long decaying tail after an initial peak. 
The histogram of the model data has no initial peak, but only a long tail. Additional 
information concerning the properties of these distributions can be obtained using 
hazard rates.
 
Figure 7. The histograms of the SWD durations, for the saline and the 500 mg/kg vigabatrin treated rats, and the 
 model using the reference parameters (truncated at 95% of the data).
Figure 6 (right panel) shows the hazard rate as a function of the SWD duration. For 
the saline treated rats, the hazard rate is monotoneously increasing whereas for the 
vigabatrin treated rats there is only an initial increase, after which there is a horizontal 
course for the largest part of the SWD durations. In the vigabatrin group, at the largest 
SWD durations the hazard rate even tends to decrease. In the model data, the hazard 
rates of the SWD durations tended to be horizontal irrespective of location and degree 
of GABA concentration manipulation. Also, overall, the absolute value of the hazard 
rate is higher in the model than in rats.
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6.4. Discussion
 In this study we analysed the inﬂuence of vigabatrin on SWDs in vivo in 
WAG/Rij rats, an animal model for absence seizures and simulated the data with a 
computational model in which we studied the inﬂuence of modulating concentrations 
of GABA. In vivo, we found that application of vigabatrin increased the total duration of 
SWDs in a dose dependent manner. Also, it altered the seizure morphology: the SWD 
peak frequency was decreased (see ﬁgure 3). Despite the change in morphology the 
analysed SWDs after vigabatrin are genuine SWDs since the SWDs after vigabatrin 
are in an equal fraction accompanied with vibrissal twitches as the SWDs after saline, 
and thus share similar clinical manifestations. Generally, an increased GABAergic 
neurotransmission aggravates absence seizures (King, 1979). Accordingly, the 
increased total duration of the SWDs after vigabatrin agrees with the mechanism 
of action of the drug, since vigabatrin, an irreversible GABA transaminase inhibitor 
(Hammond and Wilder, 1985), increases GABA concentrations in the brain. However, 
the mechanisms by which an increase of GABA can result in an exacerbation of 
seizures are still unknown. Taking into account that the cortical hyperexcitability in 
WAG/Rij rats, measured by extra- and intracellularly recorded synaptic responses, 
was demonstrated to be due to a decrease in GABA-mediated inhibition (Luhmann et 
al., 1995), we hypothesise that the action of vigabatrin is not homogeneous within the 
brain. This hypothesis agrees with the effects of vigabatrin on concentrations of GABA 
in distinct regions in the rat brain (Sills et al., 2003).
 Our modelling of the effects of vigabatrin on SWDs can be used to test this 
hypothesis. Simulations of manipulation with GABA concentrations in the whole 
thalamocortical network, or only part of the network showed that the effects of 
vigabatrin are reproduced best by an relative increase of GABA concentration at 
the level of the thalamic relay nucleus (TC cells). Only the increase of GABA level 
at the latter location monotonously increased the total duration of seizures and 
decreased their peak frequency, while an increase of GABA at other locations had 
negligible, opposite or biphasic effects (see ﬁgure 2, 4). Indeed, these simulation 
results are consistent with the microinjection studies in a similar animal model of 
absence epilepsy namely GAERS (Genetic Absence Epilepsy Rat from Strasbourg) 
rats. In GAERS, administration of vigabatrin into the thalamic relay nuclei resulted 
in exacerbation of paroxysmal discharges while administration of this drug into the 
thalamic reticular nucleus resulted in inhibition of spike and wave discharges (Liu et 
al., 1991).
 Considering our experimental and simulation results we may conclude that 
vigabatrin most likely affects inhomogeneously different parts of the thalamocortical 
circuitry.  More speciﬁcally, the in vivo results and the model would match when an 
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increase of GABAergic neurotransmission due to application of vigabatrin is most 
pronounced at the level of the thalamic relay nuclei. Interestingly, it has been shown by 
Sheikh and Martin (1998) that there are signiﬁcant regional differences in vigabatrin-
induced changes in brain GABA levels. This increase was most pronounced in the 
frontal cortex and hippocampus, when the GABA level was measured directly from 
the brain samples. However, the reduction of glutamate decarboxylase (GAD) which 
is sensitive to an increase of GABA concentration, also after vigabatrin (Rimvall and 
Martin, 1994), was largest in the cerebellum and thalamus. Therefore, the above 
mentioned results concerning the exact location of the largest GABA increase were 
ambiguous and more experimental data is necessary to validate our model’s prediction.
In this respect it may be interesting to note that Destexhe (1999) thoroughly 
investigated SWD peak frequencies in a detailed computational model of SWD 
generation in rodents. He showed that manipulation with GABAergic conductances 
in the thalamocortical cells may alter the frequency of SWDs. Despite the fact that 
manipulation with GABAA and GABAB conductances may have similar but not identical 
effects as the manipulation of GABA concentration, due to the non-linear activation 
properties of GABAB receptors (Kim et al., 1997), his results (ﬁgure 3 in Destexhe, 
1999) suggest that for a certain range of GABAergic conductances a simultaneous 
increase of both GABAA and GABAB components in the thalamocortical cells may 
decrease the SWD oscillation frequency.
 Hazard rates of durations of SWDs and normal epochs have never been 
investigated before, to the best of our knowledge, despite their potential to reveal 
additional information about the underlying mechanisms of SWDs. Hazard rates 
of durations of the inter-SWD intervals and SWD durations underwent a change 
following application of the drug. The hazard rates of inter SWD durations were 
decreasing in both conditions. However, overall, in the vigabatrin group the absolute 
value of the hazard rate was higher. In drug free (saline) conditions the hazard rate 
of SWD durations was monotoneously increasing while after application of 500 mg/kg 
of vigabatrin the course of the hazard rate of SWD durations was predominantly 
horizontal. 
 The basic assumption concerning the mechanism of generation of SWDs is 
that the thalamocortical network may exhibit bistability (i.e. coexistence of two stable 
states) between normal and paroxysmal states. The transitions from one state to 
another occur in a random fashion due to ﬂuctuations of parameters of the network 
(Suffczynski et al., 2004). The hazard rates of durations of the normal epochs, the 
inter-SWD intervals, reﬂect the mechanism of SWD initiation. In the saline condition 
as well as in the vigabatrin condition, these hazard rates were decreasing. These 
data suggest that the chance of termination of inter SWD epochs, which is equivalent 
to the onset of a paroxysmal epoch, decreases as the duration of the normal epoch 
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increases.  Furthermore, these hazard rates shown that the highest chance of having 
the next SWD is immediately after the previous SWD.
 Interestingly, Meeren et al. (2002) demonstrated that SWDs are initiated in 
the somatosensory cortex. Also, an impaired hyperpolarisation-activated mixed ionic 
Ih current was recently shown in the somatosensory cortex of WAG/Rij rats (Strauss 
et al., 2004), suggesting a role for Ih in the generation of SWDs. At the network 
level, the burst ﬁring associated with a decrease in Ih, may provide a basis for the 
synchronisation of large assemblies of neurons. Then, a higher degree of synchrony 
in the ﬁring of cortical neurons might lead to an increased probability of driving the 
thalamocortical networks, ultimately inducing oscillatory phase-locked ﬁring between 
cortical and thalamic neurons, the major component of SWDs (Strauss et al., 2004). 
Then, the observed decaying hazard rates of the durations of the inter-SWD intervals 
in the saline group suggest that, when there recently has been a SWD, it might be 
easier to regain synchronous network ﬁring and thus the probability of initiating a new 
SWD is highest. This would suggest that SWDs are likely to cluster, which is supported 
by data of Midzyanovskaya et al. (2004).  After vigabatrin, the overall probability that 
a SWD will start is increased, as was shown by the overall higher value of the hazard 
rates of the duration of the inter-SWD intervals. Possibly, the hyperpolarisation as 
a result of the activation of GABA receptors would facilitate the burst ﬁring mode of 
the neurons. By facilitating the burst ﬁring mode, and thereby increasing the network 
synchrony, the overall probability of the starting of a SWD is increased.
 The hazard rates of durations of SWDs were increasing in saline conditions, 
indicating that the chance that the SWD stops in the next instant of time increases 
as the SWD duration increases. These results may suggest that SWDs in drug free 
animals are terminated by a time-dependent process. A possible candidate might 
be the extracellular calcium concentration which drops to levels incompatible with 
efﬁcient synaptic transmission during spike and wave seizures in cats, probably due to 
postsynaptic calcium entry (Amzica et al., 2002). Furthermore, calcium upregulation of 
the hyperpolarisation-activated mixed ionic Ih current may play a role in the termination 
of a paroxysmal burst (Bal and McCormick, 1996; Luthi and McCormick, 1998; Luthi 
and McCormick, 1999).  
 In the light of the two mechanisms mentioned above, it is interesting to 
compare the hazard rate of durations of SWDs in the saline condition with those 
obtained after administration of vigabatrin. The latter had a horizontal course indicating 
that the chance that the SWD stops in the next instant of time stays constant as the 
SWD duration increases. These results suggest that GABAergic neurotransmission 
may be related to seizure cessation, since vigabatrin was shown to affect the hazard 
rate of SWD durations. If, e.g., SWDs are terminated due to progressive depolarisation 
of TC cells as a result of the hyperpolarisation-activated Ih current, but if there is also 
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an excess of GABA (e.g., due to vigabatrin treatment) then TC cells are strongly 
hyperpolarised even when Ih is activated. In such case the mechanism of seizure 
termination which is active in the saline condition would be switched off under 
vigabatrin.
 We should note however, that the hazard rates of the durations of the inter-
SWD intervals and SWD durations of the model had a horizontal course. Indeed, in the 
model no (deterministic) mechanism was included that stops or starts the SWDs, and 
only Gaussian noise (giving a constant hazard rate) is responsible for this process. 
Therefore, the model does not share the same mechanisms of SWD initiation and 
termination, leaving room for further improvement of the model. 
 In conclusion, we found that application of vigabatrin increased the total 
duration of SWDs, while the SWD peak frequency was decreased. Furthermore, 
hazard rates of durations of inter-SWD intervals and SWD durations underwent a 
change following application of the drug. The computational thalamocortical model 
accords with this in vivo data, except for the hazard rates, on the assumption that an 
increase of GABA concentration due to application of vigabatrin is most pronounced at 
the level of the thalamic relay nuclei. Furthermore, since vigabatrin was shown to affect 
the course of the hazard rates of SWD durations, it might be assumed that GABA in 
TC cells is actively involved in the process of absence seizure termination. Moreover, 
it suggests that the SWD stopping mechanism can be blocked by an excess of GABA. 
Implementing such a stopping mechanism would further improve the computational 
model, possibly allowing for truly realistic predictions.
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Abstract
 The effects of several GABAergic drugs (loreclezole, diazepam, etomidate, 
Org 205999, vigabatrin and R-baclofen) on the spike and wave discharges (SWDs) in 
the electroencephalogram (EEG) of WAG/Rij rats were studied. The effects on SWD 
incidence, SWD duration and inter SWD duration were investigated. Furthermore, 
hazard rates were analysed in order to reveal more information on the underlying 
mechanisms of the absence epileptic SWDs. In general, the GABAergic drugs, with 
the exception of diazepam and loreclezole, increased the SWD activity (incidence, 
duration or both). Hazard rate analysis revealed that in control conditions the 
probability of a SWD starting decreases the longer the time since the last SWD. 
Increased GABAergic neurotransmission in general, increases the probability that 
a SWD will start. Nevertheless, also after the GABAergic drugs the probability of a 
SWD starting decreases the longer the time since the last SWD. In control conditions, 
the probability of an ongoing SWD stopping increases the longer the SWD lasts. 
Increased GABAergic neurotransmission in general, decreases the probability that an 
ongoing SWD will stop. Moreover, GABAB related neurotransmission is suggested to 
speciﬁcally affect the SWD stopping mechanism. These results support the suggestion 
that the hyperpolarisation activated Ih current might underlie the stopping of an ongoing 
SWD.
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7.1. Introduction
 Absence or “petit mal” seizures, also called “absences” are stereotyped 
generalised seizures with a highly characteristic electroencephalographic and 
behavioural pattern. The absence epileptic human electroencephalogram (EEG) as 
well as that of animal models of absence epilepsy are characterised by generalised 
spike and wave discharges (SWDs). Because absence epilepsy mainly affects children 
and adolescents, and has moderate consequences, studies of the pathophysiological 
mechanisms cannot be conducted in humans for ethical reasons. Therefore, much 
of the recent information available about the pathophysiology of absence epilepsy 
is derived from studies in animal models (Marescaux et al., 1992b; Coenen and van 
Luijtelaar, 2003).
 The WAG/Rij rat, an inbred strain of rats, is recognised as an animal model 
of human absence epilepsy (Van Luijtelaar and Coenen, 1986; Coenen and van 
Luijtelaar, 2003). Similar to the case of human absence epilepsy, mild behavioural 
concomitants such as accelerated breathing, twitching of the vibrissae and tiny head 
jerks, are visible during the presence of a SWD in the EEG of the WAG/Rij rat (Van 
Luijtelaar and Coenen, 1986; Coenen and van Luijtelaar, 2003). These rats have about 
16-20 SWDs per hour, with an average duration of about 5 sec (Van Luijtelaar and 
Coenen, 1986; Coenen and van Luijtelaar, 2003). Furthermore, the effects of anti-
epileptic drugs in the WAG/Rij rats, are similar to effects in human absence epilepsy. 
Indeed, anti-absence drugs cause a decrease in the SWD activity, whereas several of 
the anticonvulsive drugs (often GABA agonists) trigger a substantial increase (Peeters 
et al., 1988; Coenen et al., 1995; Avanzini and Franceschetti, 2003; Coenen and van 
Luijtelaar, 2003).
 The cellular mechanisms underlying the SWDs involve complex intrinsic ﬁring 
properties of thalamic and cortical neurons, which interact through multiple types 
of synaptic receptors. Unfortunately, due to the complexity of these interactions, 
the detailed sequence of events underlying the SWDs in the EEG remains unclear 
(Niedermeyer, 1996). Nevertheless, it has been shown that both cortical and thalamic 
neurons are necessary to generate SWDs and that GABAergic neurotransmission is 
actively involved (Gloor et al., 1977; Hosford et al., 1992; Snead, 1992; von Krosigk et 
al., 1993; Puigcerver et al., 1996; Steriade and Contreras, 1998; Meeren et al., 2002). 
For the development of new antiepileptic drugs, information about these underlying 
mechanisms is essential. By means of observing the effects of alterations in the 
neurotransmitter systems on various parameters of the SWDs, as can be obtained by 
pharmacological manipulations, more can be learned about the mechanisms relevant 
in absence epilepsy.
 Gamma-aminobutyric acid (GABA) is generally believed to be implicated in 
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the occurrence and control of SWDs (Crunelli and Leresche, 2002). The GABAergic 
neurotransmission system contains two major receptor types, the GABAA and GABAB 
receptors. The GABAA receptor is an ionotropic receptor with a chloride (Cl
-) channel, 
whereas the GABAB receptor is a metabotropic receptor coupled to calcium (Ca
2+) and 
potassium (K+) channels (Bowery et al., 2002). Both GABAA and GABAB receptors are 
activated by their natural agonist GABA. 
 Since GABA itself is unable to pass the blood-brain barrier and is metabolised 
very quickly, systemic injection of GABA has no effect on GABA concentrations in the 
brain. Therefore, in order to experimentally manipulate GABA concentrations in the 
brain, compounds that interfere with the normal re-uptake and metabolic inactivation 
of GABA can be used. One of such compounds is the irreversible GABA transaminase 
(GABA-T) inhibitor vigabatrin (γ-vinyl-GABA) (Hammond and Wilder, 1985). Vigabatrin 
binds irreversibly to the enzyme, and enzymatic activity therefore only recovers 
when new enzyme is synthesized. Indeed, after a single systemic administration of 
vigabatrin, GABA-T activity decreases, and GABA levels increase throughout the brain 
(Hammond and Wilder, 1985; Valdizán et al., 1999; Tong et al., 2000). Furthermore, 
GABA-T levels decrease rapidly, reaching a minimum level of about 20% of the control 
level within 3 to 4 hours after vigabatrin administration. This level is maintained for 
about 48 hours and then rises slowly, because of new enzyme synthesis (Hammond 
and Wilder, 1985). Whole brain GABA concentrations are maximally increased 4 
hours after injection; this level is maintained for 24 hours and then declines slowly 
(Hammond and Wilder, 1985; Valdizán et al., 1999). By increasing endogenous GABA 
concentrations both the GABAA and GABAB neurotransmission is favoured.
 Furthermore, the GABAA receptors contain several binding sites; an agonist 
site (binding GABA, muscimol), a picrotoxin site, sites for allosteric modulators such 
as: benzodiazepines, neuroactive steroids, barbiturates, ethanol, and sites for other 
compounds such as stereoselective inhalation anaesthetics, furosemide, Zn2+ ions, 
divalent cations and La3+ ions (Johnston, 1996). Binding of GABAA agonists results 
in the opening of the Cl- channel, Cl- inﬂux and hyperpolarisation, eventually leading 
to fast inhibitory postsynaptic potentials (IPSPs) which decrease the ﬁring rate of the 
postsynaptic neuron. Furthermore, the allosteric modulators of the GABAA receptor 
enhance the opening frequency and/or the opening duration of the Cl- channel, when 
the channel is activated as a result of the binding of a GABAA agonist (reviewed 
in Korpi et al., 2002). The binding of agonists to the GABAB receptor results in the 
activation of G proteins, which causes a decrease in Ca2+ and an increase in K+ 
membrane conductance (Bowery and Enna, 2000) eventually leading to slow IPSPs.
In general, stimulation of GABAA and/or GABAB receptors causes an exacerbation of 
the SWDs in animal models of absence epilepsy (Vergnes et al., 1984; Peeters et al., 
1988; Peeters et al., 1989; Coenen et al., 1995; Marescaux et al., 1992a; Marescaux 
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et al., 1992b; Coenen and van Luijtelaar, 2003). Interestingly, the benzodiazepines 
have been shown to decrease the SWD activity (Marescaux et al., 1992b; Coenen and 
van Luijtelaar, 2003). Most likely, the reason for this dichotomy is that benzodiazepines 
enhance GABAA receptor mediated inhibition speciﬁcally within the reticular thalamic 
nucleus (Rtn), due to their subunit speciﬁc binding, leading to increased intra-Rtn 
inhibition, resulting in a decreased inhibition by the Rtn of the thalamic relay nuclei 
(Huguenard and Prince, 1994; Wong and Snead, 2001).
 Investigating the effects of pharmacological manipulations with GABAergic 
drugs on SWDs might provide further knowledge on the underlying mechanisms of 
the absence epileptic SWDs. Therefore, in the present study, the effects of several 
GABAergic drugs on the duration and incidence of SWDs, as well as the inter SWD 
duration; in the EEG of WAG/Rij rats were studied. Furthermore, histograms of the 
SWD durations and inter SWD durations were constructed, and the hazard rates were 
analysed in order to reveal more information on the underlying mechanisms of the 
absence epileptic SWDs.
7.2. Materials and methods
 This study was performed in accordance with the guidelines of the European 
Community for the use of experimental animals. Approval of the local ethical 
committee for animal studies was obtained.
 Adult male WAG/Rij rats were used. Animals were individually housed in 
Macrolon cages, and were maintained on a reversed 12-h light-dark cycle with lights 
on at 20.00 h. Food and water were available ad libitum. A permanent cortical tripolar 
electrode (Plastics One MS-332/2-A) was implanted under complete isoﬂurane 
anaesthesia, one electrode in the frontal region (coordinates with the skull surface ﬂat 
and bregma zero-zero: A 2.0, L 3.5), and the other in the parietal region (A –6.0, L 4.0) 
(Paxinos and Watson, 1997). The ground electrode was placed over the cerebellum. 
The electrodes were ﬁxed to the skull using two stainless-steel screws and dental 
acrylic. After the surgery, the animals were allowed to recover for at least 2 weeks.
 Rats were placed into transparent recording cages, connected to an EEG 
cable, and habituated to the experimental conditions during 1 h. Experimental 
sessions were performed between 9:00 and 17:00 h. The rats were injected i.p. with 
saline (n=9), intralipid (n=9), 500 mg/kg vigabatrin (n=9), 5 mg/kg R-baclofen (n=9), 
10 mg/kg diazepam (n=8), 20 mg/kg loreclezole (n=8), 5 mg/kg etomidate (n=8) or 
60.8 mg/kg Org 20599 (n=6). Vigabatrin, R-baclofen and Org 20599 were dissolved in 
saline (0.9% NaCl), whereas diazepam, loreclezole and etomidate were dissolved in 
intralipid.
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For a 30 min period (for intralipid, loreclezole and etomidate 60 min), starting 15 min 
after injection (for vigabatrin 6 hours after injection) the EEG was measured. The EEG 
in a bandwidth between 1 and 100 Hz, was digitalised with a sample frequency of 512 
Hz, and stored for an off-line analysis using the Windaq system (DATAQ Instruments, 
OH, USA). The SWDs were marked after visual inspection based on the criteria for 
standard SWDs as proposed by van Luijtelaar and Coenen (1986).
 The incidence, average duration and the average inter SWD duration were 
off-line determined. Statistical analyses, comparing the effect of a drug with its control, 
were performed using independent samples T-tests in SPSS 11.5 for Windows (SPSS 
Inc., Chicago, Illinois USA). A signiﬁcance level of 0.05 was used.
 We obtained histograms of SWD durations and inter SWD durations. These 
histograms were transformed into hazard rates by a modiﬁcation of the estimation 
algorithm of Müller and Wang (1994) (see Maris et al., in press, for details). The 
hazard rate of the SWD durations can be interpreted as the instantaneous probability 
of stopping the SWD as a function of time. The time course of this instantaneous 
stopping probability reveals information about the underlying SWD stopping 
mechanism (see Maris et al., in press). The hazard rate of the inter SWD durations can 
be interpreted as the instantaneous probability of starting a SWD as a function of time. 
The time course of this instantaneous starting probability reveals information about the 
underlying SWD starting mechanism (see Maris et al., in press). 
7.3. Results
7.3.1. Average SWD duration
 Table 1 shows the average duration of the SWDs per treatment. Statistical 
analyses show that there is no difference between the saline and intralipid treatment. 
Also, the average SWD duration is signiﬁcantly increased after etomidate (t(14)=-2.921; 
P<0.05) and R-baclofen (t(16)=-2.282; P<0.05) as compared to their control. 
Furthermore, the average SWD duration is signiﬁcantly decreased after loreclezole 
(t(14)=2.884; P<0.05) and diazepam (t(7)=12.14; P<0.001) as compared to their control.
7.3.2. Inter SWD duration
 Table 1 shows the average inter SWD duration per treatment. Statistical 
analyses show that there is no difference between the saline and intralipid treatment. 
Also, the inter SWD duration is signiﬁcantly decreased after etomidate (t(7)=3.372; 
P<0.05), vigabatrin (t(16)=2.232; P<0.05) and R-baclofen (t(8)=2.611; P<0.05) as 
compared to their control. 
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7.3.3. Incidence of SWDs
 Table 1 shows the incidence of the SWDs per treatment. Statistical analyses 
show that there is no difference between the saline and intralipid treatment. Also, 
the SWD incidence is signiﬁcantly increased after etomidate (t(9)=-9.084; P<0.001), 
Org 20599 (t(5)=-2.653; P<0.05), vigabatrin (t(8)=-3.482; P<0.01) and R-baclofen 
(t(9)=-7.987; P<0.001) as compared to their control. Furthermore, the SWD incidence 
is signiﬁcantly decreased after loreclezole (t(8)=5.511; P<0.01) and diazepam 
(t(9)=5.656; P<0.001) as compared to their control. 
Table 1.The effects of the different treatments on the SWD duration, inter SWD 
 duration and the incidence of the SWDs. 
Treatment SWD duration (sec) Inter SWD duration 
(sec)
SWD incidence  
(per 30 min)
Saline 6.20 ± 0.67 187 ± 65 9.56 ± 1.97
Intralipid 6.19 ± 0.47 180 ± 43 9.44 ± 1.28
Loreclezole 3.97 ± 0.61* 809 ± 325 2.13 ± 0.35*
Diazepam 0.48 ± 0.03* 655 ± 238 1.67 ± 0.50*
Etomidate 9.60 ± 1.07* 33.5 ± 3.4* 41.5 ± 3.28*
Org 20599 7.75 ± 0.82 60.5 ± 22 40.8 ± 11.6*
Vigabatrin 6.28 ± 0.81 39.0 ± 13* 60.6 ± 14.5*
R-baclofen 10.0 ± 1.53* 16.9 ± 3.0* 70.1 ± 7.32*
  
Means with standard errors. Asterisks indicating statistical signiﬁcances compared to corresponding control.
The inverse calculation does not necessarily amount to 1800 sec due to the averaging procedure and missing 
values.
7.3.4. Hazard rates of SWD durations
 Figure 1 shows the histograms of the SWD durations per treatment. Figures 2-
4 show the hazard rate as a function of the SWD durations, per treatment. In the saline 
group the hazard rate is increasing as a function of the SWD duration. 
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Figure 1. The histograms of the SWD duration per treatment.
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 Figure 2 shows that also the hazard rates of loreclezole and diazepam groups 
are increasing as a function of the SWD duration. Moreover, the hazard rates of the 
diazepam group have an exceptionally steep course.  Also, the absolute values of 
the hazard rates tend to be higher after these treatments. Thus, in controls and after 
diazepam and loreclezole the probability of the SWD stopping increases as the SWD 
duration increases. Furthermore, the absolute probability of a SWD stopping tends to 
be higher after these treatments.
   
 
Figure 2. The hazard rates (truncated at 99%) of the SWD durations for the saline, loreclezole and diazepam 
 treatments.
 Figure 3 shows that also the hazard rates of the Org 20599 group are 
increasing as a function of the SWD duration, whereas after etomidate there is only an 
initial increase followed by a constant/ﬂat course of the hazard rates and after a certain 
SWD length the hazard rates tend to decrease. Also, the overall absolute values of the 
hazard rates tend to be lower after these treatments. Thus, in controls and after Org 
20599 the probability of the SWD stopping increases as the SWD duration increases, 
whereas after etomidate this probability has an initial increase and tends to decrease 
for the largest SWD durations, but stays constant for most of the SWD durations. 
Furthermore, the overall absolute probability of a SWD stopping tends to be lower after 
these treatments.
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Figure 3. The hazard rates of the SWD durations for the saline, Org 20599 and etomidate treatment.
 Figure 4 shows that also the hazard rates of the vigabatrin group show an 
initial increase for the short SWD durations followed by constant hazard rates for 
most of the SWD durations and after a certain SWD length the hazard rates tend to 
decrease. For the R-baclofen group the hazard rates tend to be constant for most of 
the SWD durations and after a certain SWD length the hazard rates tend to decrease. 
Also, the absolute values of the hazard rates tend to be lower after these treatments. 
Thus, after vigabatrin the probability of the SWD stopping initially increases and tends 
to decrease for the very long SWDs, but stays constant for most of the SWD durations. 
After R-baclofen the probability of the SWD stopping tends to decrease for the very 
long SWDs, but stays constant for most of the SWD durations. Furthermore, the 
absolute probability of a SWD stopping tends to be lower after these treatments.
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Figure 4. The hazard rates (truncated at 99%) of the SWD durations for the saline, vigabatrin and R-baclofen 
 treatments.
7.3.5. Hazard rates of inter SWD durations
 Figure 5 shows the histograms of the inter SWD durations per treatment. 
Figures 6-8 show the hazard rate as a function of the inter SWD durations, per 
treatment. In the saline group the hazard rate is decreasing as a function of the inter 
SWD duration.  
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Figure 5. The histograms of the inter SWD durations per treatment.
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 Figure 6 shows that the hazard rates of loreclezole and diazepam groups 
are slightly decreasing as a function of the inter SWD duration. Also, the absolute 
values of the hazard rates tend to be lower after these treatments. Thus, in controls 
the probability of a SWD starting decreases as the inter SWD duration (time since the 
last SWD) increases. After loreclezole and diazepam the probability of a SWD starting 
tends to decrease as the inter SWD duration increases. Furthermore, the absolute 
probability of a SWD starting tends to be lower after these treatments.
 
 
Figure 6. The hazard rates of the inter SWD durations for the saline, loreclezole and diazepam treatment.
  Figure 7 shows that also the hazard rates of the Org 20599 and etomidate 
groups are decreasing as a function of the inter SWD duration. Also, the absolute 
values of the hazard rates tend to be higher after these treatments. Thus, in controls 
and after Org 20599 or etomidate the probability of a SWD starting decreases as the 
inter SWD duration increases. Furthermore, the absolute probability of a SWD starting 
tends to be higher after these treatments.
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Figure 7. The hazard rates (truncated at 99%) of the inter SWD durations for the saline, Org 20599 and etomidate 
 treatment.
 Figure 8 shows that the hazard rates of the vigabatrin and R-baclofen groups 
are decreasing as a function of the inter SWD duration. Also, the absolute values of 
the hazard rates tend to be higher after these treatments. Thus, after vigabatrin and 
R-baclofen the probability of a SWD starting decreases as the inter SWD duration 
increases. Furthermore, the absolute probability of a SWD starting tends to be higher 
after these treatments.
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Figure 8. The hazard rates (truncated at 99%) of the inter SWD durations for the saline, vigabatrin and R-baclofen 
 treatment.
7.4. Discussion
 The objective of this study was to investigate the effects of pharmacological 
manipulations with GABAergic drugs on various parameters that describe the 
properties of the SWDs. This might provide further knowledge on the underlying 
mechanisms of the absence epileptic SWDs. The average duration of the SWDs was 
signiﬁcantly increased after etomidate an R-baclofen, whereas after loreclezole and 
diazepam there was a signiﬁcant decrease. The average inter SWD duration was 
signiﬁcantly decreased after etomidate, vigabatrin and R-baclofen. Furthermore, the 
SWD incidence was signiﬁcantly increased after etomidate, Org 20599, vigabatrin and 
R-baclofen, whereas it decreased after loreclezole and diazepam.
 The decreasing effects of loreclezole and diazepam on SWD activity agree 
with earlier reports (Coenen and van Luijtelaar, 1989; Ates et al., 1992; Bouwman et 
al., 2004). Diazepam has a beneﬁcial effect on absence epilepsy, which is believed 
to be due to its subunit speciﬁc mechanism of action, speciﬁcally affecting the 
reticular nucleus of the thalamus (Huguenard and Prince, 1994; Wong and Snead, 
2001). Then, perhaps loreclezole has a similar subunit speciﬁc mechanism of action. 
Indeed, loreclezole almost only binds to GABAA receptors containing a β2 or β3 
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subunit (Sanna et al., 1996). However, etomidate, which increases the SWD activity, 
is believed to also bind to these subunits (Moody et al., 1997). Then, the differential 
results on SWD activity suggest that there is also another mechanism of action of 
loreclezole or etomidate. Indeed, it has been shown that etomidate does not only 
affect the β2 or β3 subunits of the GABAA receptors, but has more effects on GABAergic 
neurotransmission (Mantz et al., 1995), which will be discussed later.
 The increasing effects of neuroactive steroid Org 20599, etomidate, vigabatrin 
and R-baclofen on SWD incidence also agree with earlier reports (Vergnes et al., 
1984; Duysens et al., 1991; Marescaux et al., 1992a; Budziszewska et al. 1999; 
Bouwman et al 2003b; Bouwman et al 2004).
 Since the duration of a SWD is controlled by the mechanism that stops 
an ongoing SWD, the effects of the tested drugs might lead to more insight on the 
SWD stopping mechanism(s). Loreclezole and diazepam decreased the average 
SWD duration, which might indicate that these drugs strengthen the SWD stopping 
mechanism(s). Similarly, etomidate and R-baclofen increase the SWD duration, 
which might then indicate that these drugs weaken the SWD stopping mechanism(s). 
However, vigabatrin did not affect the average SWD duration, whereas it did affect 
the shape of the histogram of the SWD durations. The histograms of the inter SWD 
durations and SWD durations are believed to contain information about the SWD 
starting and stopping mechanisms respectively (Suffczynski et al., 2004). Then, a 
drug might affect the SWD stopping mechanism(s), without observing a change in 
average SWD duration. Hazard rate analysis uses the data of the histograms and can 
reveal information contained in the histograms, which might not be directly visible in 
the histograms themselves (Maris et al., in press). Indeed, more information about the 
manner of changes in the SWD starting and stopping mechanism(s) can be revealed 
by hazard rate analysis (Maris et al., in press). 
 The hazard rate analysis showed that all drugs changed the SWD stopping 
mechanism(s), albeit in a different way. Also, after loreclezole and diazepam the 
probability of an ongoing SWD stopping in the next instant of time increases the 
longer the SWD lasts, as is the case after saline. After diazepam there is an overall 
higher probability of the SWD stopping, also loreclezole seems to increase this overall 
probability. After the neuroactive steroid Org 20599, the probability of an ongoing SWD 
stopping in the next instant of time increases the longer the SWD lasts, as is the case 
after saline, loreclezole and diazepam. However, after Org 20599 there is an overall 
lower probability of the SWD stopping.
 In contrast, after etomidate, vigabatrin and R-baclofen, the course of the hazard 
rates of the SWD durations tends to be constant/ﬂat for most of the SWD durations, 
i.e. the probability of an ongoing SWD stopping in the next instant of time is constant. 
Moreover, after these drugs there is an overall lower probability of the SWD stopping. 
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 These results suggest that GABAergic neurotransmission in general is 
quantitatively involved (changes overall probabilities) in the mechanism(s) determining 
the stopping of an ongoing SWD. Furthermore, the drugs which affect GABAB 
neurotransmission, R-baclofen and vigabatrin, affect the SWD stopping mechanism(s) 
in a qualitative manner (changes course of hazard rates). Accordingly, the subunit 
speciﬁc GABAA agonist etomidate, which affects the SWD stopping mechanism(s) in 
a qualitative manner, has been shown to also decrease GABA uptake, as a result of 
which GABAA and GABAB neurotransmission might be affected (Mantz et al., 1995). 
Then, these results suggest that speciﬁcally GABAB related neurotransmission is 
(qualitatively) involved in the SWD stopping mechanism(s).
 The results suggest that SWDs in drug-free animals are terminated by a time-
dependent process. A possible candidate might be the hyperpolarisation activated 
mixed ionic Ih current in thalamocortical cells, which may play a role in the stopping 
of an ongoing SWD (Bal and McCormick, 1996; Lüthi and McCormick, 1998; Lüthi 
and McCormick, 1999). According to McCormick (2002), the generation of repetitive 
calcium spikes in thalamocortical neurons increases the intracellular calcium 
concentration resulting in the activation of calcium sensitive adenylate cyclase. This 
results in an increase in the intracellular concentration of cyclic AMP (cAMP), which 
then binds to the h-type calcium channels and promotes their open state. The opening 
of h-type calcium channels, leading to the Ih current, depolarizes thalamocortical 
cells, thereby blocking their ability to generate rebound calcium spikes and bursts of 
action potentials. Then, SWDs are terminated due to progressive depolarisation as a 
result of the hyperpolarisation-activated Ih current. As for the suggested speciﬁc role 
of GABAB in this mechanism, stimulation of the GABAB receptor inhibits adenylate 
cyclase (Wojcik and Neff, 1984) and reduces cAMP production (Barthel et al., 1996), 
thereby reducing the Ih current (Frère and Lüthi, 2004) and increasing the probability of 
a SWD to continue. The other tested GABAergic drugs quantitatively affect the SWD 
stopping mechanism, suggesting a role of GABAergic neurotransmission in general. 
Indeed, if there is also an excess of GABAergic neurotransmission (being GABAA, 
GABAB or both), e.g. due to pharmacological manipulations, thalamocortical cells are 
strongly hyperpolarised even when Ih is activated. This would then reduce the overall 
probability of a SWD stopping.
 The hazard rate analysis also showed that all tested drugs changed the SWD 
starting mechanism(s), albeit in a different way. After loreclezole and diazepam the 
probability of a SWD starting in the next instant of time tends to decrease the longer 
the time since the last SWD, which is also clearly the case after saline. However, there 
is an overall lower probability of a SWD starting after loreclezole and diazepam. After 
Org 20599, etomidate, vigabatrin and R-baclofen the probability of a SWD starting in 
the next instant of time decreases the longer the time since the last SWD, as is the 
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case after saline. However, after these drugs there is an overall higher probability of a 
SWD starting. Thus, all the tested drugs changed, either decreasing or increasing, the 
overall probability of a SWD starting.
 These results suggest that GABAergic neurotransmission in general is 
quantitatively involved in the mechanism(s) determining the starting of a SWD. 
However, no clear qualitative effect on the SWD starting mechanism(s), of the tested 
GABAergic drugs, could be observed. Meeren et al. (2002) demonstrated that SWDs 
are initiated in the cortex. Interestingly, an impaired Ih was recently shown in the 
somatosensory cortex of WAG/Rij rats (Strauss et al., 2004), suggesting a role for 
Ih in the generation of SWDs. Indeed, Schridde (2005) suggested that increased 
Ih in the somatosensory cortex is related to a decreased generation of SWDs after 
experimental manipulations.
 At the network level, the burst ﬁring associated with a decrease in Ih, may 
provide a basis for the synchronisation of large assemblies of neurons. Then, a higher 
degree of synchronisation in the ﬁring of cortical neurons might lead to an increased 
probability of driving the thalamocortical networks, ultimately inducing oscillatory 
phase-locked ﬁring between cortical and thalamic neurons, the major component of 
SWDs (Strauss et al., 2004). If this is the case, the observed pattern in the hazard 
rates of the drug-free WAG/Rij rats suggests that when there recently has been a 
SWD, it might be easier to regain synchronous network ﬁring and the probability of 
initiating a new SWD is highest. This would mean that SWDs are likely to cluster, which 
is supported by data of Midzyanovskaya et al. (2004).
 The hyperpolarisation as a result of the activation of GABA receptors (being 
GABAA, GABAB or both), would facilitate the burst ﬁring mode of the neurons. By 
facilitating the burst ﬁring mode, and thereby increasing the network synchrony, 
the overall probability of the starting of a SWD is increased. This might explain the 
observed increase in the overall probability of a SWD starting after Org 20599, 
vigabatrin, etomidate and R-baclofen.
In summary, from this study several conclusions can be drawn: 
1. The results suggest that loreclezole and diazepam might have a similar subunit/
 region speciﬁc effect, which might underlie their decreasing effect on SWD activity. 
2. In this study it was clearly shown that hazard rate analysis can be a useful tool for 
 hypothesising about the SWD starting and stopping mechanisms.
3. In control conditions, the probability of a SWD starting decreases the longer the 
 time since the last SWD. The results of this study suggest that increased 
 GABAergic neurotransmission in general, increases the overall probability that a 
 SWD will start.
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4. In control conditions, the probability of an ongoing SWD stopping increases the 
  longer the SWD lasts. The results of this study suggest that increased GABAergic 
  neurotransmission in general, decreases the overall probability that an ongoing  
 SWD will stop. Moreover, GABAB related neurotransmission is suggested to 
  speciﬁcally affect the SWD stopping mechanism. This supports the suggestion 
  that the hyperpolarisation activated Ih current might underlie the stopping of an 
  ongoing SWD. 
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8.1. The role of GABA in SWD activity
In this thesis, it was aimed to further evaluate the role of the GABAergic 
neurotransmission system in general in the mechanisms underlying absence epileptic 
SWDs. More speciﬁcally, the aim of this thesis is to investigate whether GABAergic 
neurotransmission is either quantitatively or qualitatively (or both) involved in the 
mechanisms underlying SWDs and whether this involvement is speciﬁcally determined 
by GABAA or GABAB mediated neurotransmission. 
 First, in order to evaluate the effects of GABAergic neurotransmission in 
general (both GABAA and GABAB mediated neurotransmission) on the properties of 
type II SWDs, in chapter 2 the effects of the GABA transaminase inhibitor vigabatrin 
on type II SWDs in ACI were investigated. This study showed that vigabatrin not only 
increases type II SWD activity, but also affects the peak frequency of the type II SWDs, 
as was the case for the “normal” type I SWDs as was shown in the following chapters 
(chapters 3, 4 and 5). Furthermore, in this study it was shown that these properties of 
the SWDs were affected by vigabatrin in a time dependent manner. Next, in chapters 
3 and 4, aimed to determine whether GABAA and GABAB mediated neurotransmission 
play a differential role in determining the different properties of SWDs, the effects of 
vigabatrin, neuroactive steroid Org 20599 and GABAB agonist R-baclofen on the SWD 
activity were investigated in WAG/Rij rats. These studies showed that these drugs 
differ in their effects on several properties of the SWDs, and that GABAA and GABAB 
mediated neurotransmission indeed differentially affect the properties of the SWDs. In 
chapter 5, the effects of vigabatrin on SWDs in WAG/Rij rats were further investigated. 
This study showed that vigabatrin not only increases SWD activity, but also affects 
the peak frequency of these SWDs, as was shown in the previous chapters. Besides 
these quantitative effects vigabatrin affected the SWD stopping mechanism, as 
reﬂected by hazard rates, in a qualitative way. Furthermore, the time course of these 
effects corresponds to the reported time course of the effects on GABA concentrations 
(Hammond and Wilder, 1985; Valdizán et al., 1999) and with the time course of the 
effects on type II SWDs (see chapter 2).
 Based on the previous chapters, it might be concluded that GABAA and GABAB 
mediated neurotransmission differentially affect the properties of the SWDs and thus 
have a differential role in the mechanisms underlying the SWDs. Furthermore, it was 
shown that systemically administered vigabatrin, a drug affecting both GABAA and 
GABAB mediated neurotransmission, has pronounced effects on the SWDs, such 
as a decrease of the peak frequency of the SWDs. Then the question, from which 
parts of the thalamocortical network the effects of vigabatrin originate, arose.  In 
order to answer this last question, in chapter 6 the effects of vigabatrin on SWDs in 
WAG/Rij rats were simulated in a computational model. This study showed that the 
General discussion
107
effects of vigabatrin on SWD activity can be reproduced best by a relative increase 
in GABAergic neurotransmission at the level of the thalamic relay nucleus (TC cells). 
Furthermore, since vigabatrin was shown to affect the hazard rate of SWD durations, it 
might be assumed that GABAergic neurotransmission in TC cells is actively involved in 
the process of absence seizure termination.
 Then, the question remained whether the GABAergic neurotransmission is 
either quantitatively or qualitatively (or both) involved in the mechanisms underlying 
the starting and stopping of the SWDs, and whether GABAA and GABAB mediated 
neurotransmission are differentially involved in these mechanisms. To answer this 
question, in chapter 7 the effects of several GABAergic drugs on the SWD activity in 
WAG/Rij rats were investigated. This study showed that in control rats the probability 
of a SWD starting decreases as the time since the last SWD increases, and that the 
probability of a SWD stopping increases the longer the SWD lasts. This study also 
showed that the benzodiazepine diazepam and GABAA agonist loreclezole (β2 and β3 
subunits) have anti-absence effects, and these effects are reﬂected in the effects on 
the hazard rates of the SWD durations and inter SWD durations. Neuroactive steroid 
Org 20599 was shown to have pro-absence effects, and the effects on the hazard 
rates show that after Org 20599 the probability of a SWD stopping increases the longer 
the SWD lasts and the probability of a SWD starting decreases as the time since the 
last SWD increases. Also, after Org 20599 the overall probability of a SWD starting is 
increased and the overall probability of a SWD stopping is decreased. This study also 
showed that after vigabatrin, GABAB agonist R-baclofen and GABAA agonist etomidate 
(β2 and β3 subunits), the SWD activity was increased. After these drugs, not only the 
overall probabilities of a SWD starting or stopping were affected, but also the course of 
the hazard rates was shown to be affected.
 To summarise, manipulation of different types of GABA receptors was shown 
to differentially affect the SWD activity. In this thesis, systemic administration of GABA 
agonistic drugs resulted in an enhancement of SWD activity, with the exception of 
diazepam and loreclezole (discussed in 8.1.3.). Next, the effects of the drugs will be 
discussed for the different aspects of SWD activity, and the observed effects will be 
related to biological mechanism(s) that might be involved.
8.1.1. Differential effects of GABAA and GABAB; SWD 
peak frequency
 Typically, the SWD peak frequency in drug-free WAG/Rij rats was between 8-9 
Hz (chapter 3, 4 and 5; see ﬁgure 1). Org 20599 (chapter 3), loreclezole and diazepam 
(unpublished observations) did not affect the SWD peak frequency. Interestingly, 
vigabatrin (chapters 2, 3, 4 and 5; see ﬁgure 1) and R-baclofen (chapter 4; see ﬁgure 1) 
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were shown to decrease the SWD peak frequency.
 
Figure 1. Typical SWDs of WAG/Rij rats after saline, vigabatrin (500 mg/kg) and R-baclofen (5 mg/kg). On the 
 right, close-ups of the SWDs are depicted.
 Therefore, increasing the GABAB (and not GABAA) related neurotransmission 
seems to be responsible for our observed drug induced decreases in SWD peak 
frequency. 
It has been proposed that the peak frequency of SWDs is determined by the receptor 
type (GABAA or GABAB) mediating the inhibition in TC cells (Destexhe, 1999; Destexhe 
and Sejnowski, 2003; see ﬁgure 2). Furthermore, it was predicted that (relatively) 
enhancing GABAB-related neurotransmission in TC cells should slow down the peak 
frequency of SWDs (Destexhe, 1999; Destexhe and Sejnowski, 2003), which was 
conﬁrmed in this thesis (chapter 3).
 Also, the computational modelling of Destexhe (1999) suggests that SWDs 
with different peak frequencies are part of continuum of oscillatory states governed 
by the same thalamocortical circuit (see ﬁgure 2). This agrees with the observations 
during the experiments included in this thesis, that the observed SWDs with a 
Saline
Vigabatrin
R-baclofen
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lower peak frequency are not so called “de novo” SWDs but instead are (more or 
less) gradually transformed from SWDs with an original peak frequency. A similar 
observation was made by Kostopoulos et al. (1981) in an experiment in which 
penicillin, suggested to be a GABAA antagonist (Sugimoto et al., 2002; Lindquist et 
al., 2004), was administered to cats (see ﬁgure 2). Furthermore, the observation of 
vibrissal twitches in this thesis (chapter 6) shows that the SWDs with a lower peak 
frequency are accompanied by vibrissal twitches as often as the SWDs with an original 
peak frequency. This observation indicates that the SWDs with a lower peak frequency 
are absence epileptic phenomena, albeit of a lower peak frequency.
 
Figure 2. The dependence of SWD peak (oscillation) frequency on GABAergic neurotransmission (left panel) and 
 EEG samples from 5 successive periods of recording before and after the administration of penicillin in 
 a cat (right panel). Adapted from Destexhe (1999) and Kostopoulos et al. (1981) respectively.
 Interestingly, a dose of 10 mg/kg etomidate (in contrast to the dose of 5 
mg/kg etomidate that was used in this thesis) was also shown to decrease the SWD 
peak frequency (Duysens et al., 1991), suggesting a GABAB stimulating activity 
of etomidate. Indeed, besides its action as a subunit speciﬁc (β2 and β3 subunits) 
agonist of the GABAA receptors (Moody et al., 1997), etomidate has been suggested 
to decrease the uptake of GABA, as a result of which both GABAA and GABAB 
neurotransmission might be increased (Mantz et al., 1995). This extra mechanism of 
action might also explain the observed differential effects of loreclezole (anti-absence) 
and etomidate (pro-absence) on the SWD activity.
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8.1.2. GABA and the mechanisms underlying SWD activity
 It was shown that hazard rate analysis can be a useful tool for hypothesising 
about the SWD starting and stopping mechanisms. Moreover, it was shown that 
this type of analysis might reveal more information on these mechanisms than the 
standard analysis of averages (of incidence and duration). Basically, the hazard rate 
is the probability that an event (starting or stopping of a SWD) occurs at the next 
instant of time given that it has not occurred yet. Then, the hazard rate of the inter 
SWD durations (time between two SWDs) can be interpreted as the instantaneous 
probability of starting a SWD given that it has not started yet. The hazard rate of 
the SWD durations can be interpreted as the instantaneous probability of stopping 
the SWD given that it has not stopped yet. The time course of these instantaneous 
probabilities reveals information about the underlying SWD starting and stopping 
mechanism(s) (Maris et al., in press).
 In general, stimulation of GABAA receptors was shown to increase the 
probability of the generation of SWDs and to decrease the probability of the cessation 
of SWDs. Stimulation of GABAB receptors was also shown to increase the probability 
of SWD generation. Moreover, GABAB receptor activation not only decreased the 
probability of the stopping of a SWD, but also changed the course of this probability as 
the SWD lasts. Next, possible biological mechanisms responsible for these effects are 
discussed.
8.1.2.1. SWD starting mechanism(s)
 Meeren et al. (2002) demonstrated that SWDs are initiated in the 
somatosensory cortex. Interestingly, an impaired Ih was recently shown in the 
somatosensory cortex of WAG/Rij rats (Strauss et al., 2004), suggesting a role for 
Ih in the generation of SWDs. Indeed, Schridde (2005) suggested that increased 
Ih in the somatosensory cortex is related to a decreased generation of SWDs after 
experimental manipulations.
 At the network level, the burst ﬁring associated with a decrease in Ih, may 
provide a basis for the synchronisation of large assemblies of neurons. Then, a higher 
degree of synchronisation in the ﬁring of cortical neurons might lead to an increased 
probability of driving the thalamocortical networks, ultimately inducing oscillatory 
phase-locked ﬁring between cortical and thalamic neurons, the major component of 
SWDs (Strauss et al., 2004). If this is the case, the observed pattern in the hazard 
rates of the drug-free WAG/Rij rats suggests that when there recently has been a 
SWD, it might be easier to regain synchronous network ﬁring and the probability of 
initiating a new SWD is highest. This would mean that SWDs are likely to cluster, which 
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is supported by data of Midzyanovskaya et al. (2004).
 It was also observed that application of GABA agonistic drugs results in an 
overall higher probability of the starting of a SWD. The hyperpolarisation as a result 
of the activation of GABA receptors (GABAA, GABAB or both) would facilitate the burst 
ﬁring mode of the neurons. By facilitating the burst ﬁring mode, and thereby increasing 
the network synchrony, the overall probability of the starting of a SWD is increased. 
8.1.2.2. SWD stopping mechanism(s)
 In this thesis it was shown that SWDs in drug-free WAG/Rij rats are terminated 
by a time-dependent process. A possible candidate might be the hyperpolarisation 
activated mixed ionic Ih current in thalamocortical cells, which may play a role in the 
stopping of an ongoing SWD (Bal and McCormick, 1996; Lüthi and McCormick, 1998; 
Lüthi and McCormick, 1999). According to McCormick (2002), the generation of 
repetitive calcium spikes in thalamocortical neurons increases the intracellular calcium 
concentration resulting in the activation of calcium sensitive adenylate cyclase. This 
results in an increase in the intracellular concentration of cyclic AMP (cAMP), which 
promotes the open state of h-channels. The opening of h-channels, leading to the Ih 
current, depolarizes thalamocortical cells, thereby blocking their ability to generate 
rebound calcium spikes and bursts of action potentials. Then, SWDs are terminated 
due to progressive depolarisation as a result of the hyperpolarisation-activated Ih 
current in thalamocortical cells (see ﬁgure 3).
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Figure 3. The two different ﬁring modes of thalamocortical cells and the suggested ionic substrates of rhythmic 
 burst ﬁring. Adapted from McCormick and Pape (1990). 
 The GABA agonistic drugs quantitatively affect the SWD stopping mechanism, 
suggesting a role of GABAergic neurotransmission in general. Indeed, if there is an 
excess of GABAergic neurotransmission (e.g. due to pharmacological manipulations), 
thalamocortical cells are strongly hyperpolarised. This would prolong the progressive 
depolarisation due to the Ih current and thus reduce the overall probability of a SWD 
stopping. 
 In this thesis, a speciﬁc role of GABAB in this mechanism was suggested. 
Indeed, stimulation of the GABAB receptor also inhibits adenylate cyclase (Wojcik and 
Neff, 1984) and reduces cAMP production (Barthel et al., 1996), thereby reducing the 
Ih current (Frère and Lüthi, 2004).
 The cessation of SWDs might also be the result of such a mechanism located 
in the cortex or Rtn. The Rtn cells are believed to show very little Ih current (Robinson 
and Siegelbaum, 2003). Therefore, the Rtn is an unlikely candidate for harbouring 
of this suggested SWD stopping mechanism, which leaves the cortex and the TC 
cells. Interestingly, the thalamocortical cells are among the brain regions having the 
highest density of GABAB binding sites (Bowery et al., 1987; Chu et al., 1990) and the 
Ih current in thalamocortical cells is believed to be highly cAMP sensitive (Seifert et al., 
1999; Santoro et al., 2000). Therefore, the thalamocortical cells are believed to be a 
prime candidate for the harbouring of this suggested SWD stopping mechanism.
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8.1.3. The SWD reducing GABA agonistic drugs
 Normally, the release of GABA from Rtn neurons onto thalamocortical neurons 
results in a membrane hyperpolarisation and associated removal of inactivation from 
a T-type calcium current, which in turn, activates upon repolarisation and triggers a 
rebound burst of fast action potentials. The transfer of this burst activity via excitatory 
synaptic connections to Rtn neurons results in correlated bursting and GABA release, 
and the cycle starts again. However, if by pharmacological manipulation the release 
of GABA from Rtn neurons onto thalamocortical neurons is prohibited, for instance by 
increasing the intra-Rtn inhibition, synchronous bursting in the thalamocortical network 
can be prevented.
 Benzodiazepines such as diazepam are believed to speciﬁcally bind to 
the GABAA receptors in the Rtn due to their subunit speciﬁc binding (see chapter 
1), thereby increasing the intra-Rtn inhibition (Huguenard and Prince, 1994; Wong 
and Snead, 2001). Indeed, benzodiazepines are clinically used as an anti-absence 
treatment (Faingold and Browning, 1987). Accordingly, in this thesis, diazepam was 
shown to decrease SWD activity. Furthermore, this anti-absence activity was also 
reﬂected in the hazard rates of the SWD durations and the inter SWD durations, which 
showed an overall increased probability of a SWD stopping and an overall decreased 
probability of a SWD starting respectively.
 Besides diazepam, also loreclezole was shown to have anti-absence 
properties, which agrees with an earlier study in WAG/Rij rats (Ates et al., 1992). The 
mechanism(s) through which this anti-absence activity is mediated are unknown. 
However, loreclezole also binds subunit speciﬁcally (β2 and β3 subunits) to the GABAA  
receptor (Sanna et al., 1996). Then, perhaps the anti-absence effects of loreclezole 
are also mediated through a subunit/region speciﬁc effect. 
8.1.4. Implications for treatment of absence epilepsy
 These proposed underlying mechanisms of absence epileptic SWDs, allow 
some speculation about possible targets for drugs in the treatment of absence 
epilepsy. Of course, most drugs do not have one speciﬁc mechanism of action, but 
have multiple mechanisms of action (so called “dirty” or “rich” drugs). Also, a speciﬁc 
target receptor or channel is likely to be involved in more processes than only those 
underlying SWD activity. Therefore, other possible effects on SWDs and other 
variables, which might limit the clinical usefulness of drugs, can not be excluded 
beforehand. Nevertheless, some possible types of drugs for the treatment of absence 
epilepsy are proposed.
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• GABAB antagonists:
 GABAB antagonists reduce the binding of endogenous GABA to the GABAB 
 receptor, which reduces/prohibits hyperpolarisation (normally induced by 
 endogenous GABA) and corresponding burst ﬁring, thereby reducing the 
 probability of a SWD starting.
 When a SWD is started, despite the reduced probability, the progressive 
 depolarisation in TC cells is enhanced, by the unaffected cAMP levels (which  
 would normally be decreased by stimulation of the GABAB receptor by 
 endogenous GABA), and the cessation of this ongoing SWD is facilitated.
 Indeed, several drugs with GABAB antagonistic properties were shown to have 
 anti-absence effects in animal models of absence epilepsy (Marescaux et al., 
 1992a; Vergnes et al., 1997; Smith and Fisher, 1996; Puigcerver et al., 1996; 
 Hosford et al., 1995; Kaminski et al., 2001).
• Drugs that increase the activation and/or the efﬁcacy of the Ih current:
 Such drugs might reduce the probability of a SWD starting, due to decreased 
 network synchrony. When a SWD is started, despite the reduced probability, the 
 progressive depolarisation in TC cells is enhanced and the cessation of this 
 ongoing SWD is facilitated.
 Interestingly, lamotrigine which has some anti-absence effects in the WAG/Rij rat 
 model for absence epilepsy (van Rijn et al., 1994) and in humans 
 (Panayiotopoulos, 2001; Choi and Morrell, 2003; Coppola et al., 2004), is 
 believed to increase the Ih current (Poolos et al., 2002).
• Drugs that speciﬁcally increase the intra-Rtn inhibition:
 These drugs might reduce/prohibit the hyperpolarisation of TC cells, thereby 
 decreasing the burst ﬁring mode of these cells and thus decreasing the 
 synchronous network bursting activity. 
 Indeed, examples of such drugs are the benzodiazepines, which are already 
 clinically used as an anti-absence treatment (Faingold and Browning, 1987). 
8.2. General conclusions
 Stimulating GABAergic neurotransmission in general aggravates the absence 
epileptic SWDs in rats. Moreover, it was shown that that GABAA and GABAB mediated 
neurotransmission are differentially involved in the mechanisms underlying the 
SWDs. By simulating the effects of the GABA transaminase inhibitor vigabatrin in a 
computational model of the thalamocortical network, it was suggested that speciﬁcally 
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the GABA mediated neurotransmission at the level of the TC cells might play an 
important role in the mechanisms underlying the SWDs. Interestingly, earlier it was 
predicted that (relatively) enhancing GABAB-related neurotransmission in TC cells 
should slow down the peak frequency of SWDs (Destexhe, 1999; Destexhe and 
Sejnowski, 2003), which was supported in this thesis by effects after vigabatrin and R-
baclofen (chapter 2, 3, 4 and 5).
 It was also shown that some GABA agonistic drugs (diazepam and loreclezole) 
have anti-absence effects (see chapter 7). These GABA mediated anti-absence 
effects are likely to be mediated through a subunit/region speciﬁc effect in the 
thalamocortical system. This stresses the level of complexity of the role of GABAergic 
neurotransmission in the mechanisms underlying the absence epileptic SWDs.
 Hazard rate analysis can be a useful tool for hypothesising about the SWD 
starting and stopping mechanisms. Moreover, it was shown that this type of analysis 
might reveal more information on these mechanisms than the standard analysis of 
averages (of incidence and duration). Using the hazard rate analysis information on 
the underlying mechanisms of the SWDs can be obtained without using more invasive 
research methods such as depth electrode measurements, local injections or lesion 
studies. 
 GABAergic neurotransmission in general is both quantitatively and qualitatively 
involved in the mechanisms underlying the SWDs. More speciﬁcally, stimulation of 
the GABAA receptors by GABAA agonistic drugs was shown to increase the probability 
of the generation of SWDs and to decrease the probability of the cessation of SWDs. 
Stimulation of GABAB receptors by GABAB agonistic drugs was also shown to increase 
the probability of SWD generation. Moreover, GABAB receptor activation not only 
decreased the probability of the stopping of a SWD, but also changed the course 
of this probability as the SWD lasts. These results indicate that GABAB mediated 
neurotransmission might be speciﬁcally involved in the mechanism(s) underlying the 
cessation of SWDs.
 Interestingly, it has been suggested that the hyperpolarisation activated mixed 
ionic Ih current in thalamocortical cells may play a role in the stopping of an ongoing 
SWD (Bal and McCormick, 1996; Lüthi and McCormick, 1998; Lüthi and McCormick, 
1999). In this thesis, it was suggested that GABAB mediated neurotransmission 
might be involved in the mechanism(s) underlying the stopping of a SWDs by 
reducing the production of cAMP thereby diminishing the inﬂuence of the Ih current in 
thalamocortical cells. 
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 First, in chapter 1, absence epilepsy is introduced. Furthermore, the biological 
circuitry believed to be involved and the GABAergic neurotransmission system is 
explained. The mechanisms of action of several GABAergic drugs are mentioned, and 
some variables that can be measured to investigate drug effects are introduced. Also, 
the hazard rate analysis is explained, since this analysis was used to investigate the 
role of GABA in the mechanisms underlying absence epilepsy.
The aim of this thesis:
 
It was aimed to further evaluate the role of the GABAergic neurotransmission 
system in the mechanisms underlying absence epilepsy. More speciﬁcally, the 
aim of this thesis is to investigate whether GABAergic neurotransmission is either 
quantitatively or qualitatively (or both) involved in the mechanisms underlying SWDs 
and whether this involvement is speciﬁcally determined by GABAA or GABAB mediated 
neurotransmission
 First, in order to evaluate the effects of GABAergic neurotransmission in 
general (both GABAA and GABAB mediated neurotransmission) on the properties 
of type II SWDs the effects of the GABA transaminase inhibitor vigabatrin on type II 
SWDs in ACI rats were investigated in chapter 2. This study showed that vigabatrin 
not only increases type II SWD activity, but also affects the peak frequency of the type 
II SWDs, as was the case for the “normal” type I SWDs as was shown in the following 
chapters (chapters 3, 4 and 5). Furthermore, in this study it was shown that these 
properties of the SWDs were affected by vigabatrin in a time dependent manner. 
Next, in chapters 3 and 4, aimed to determine whether GABAA and GABAB mediated 
neurotransmission play a differential role in determining the different properties of 
SWDs, the effects of vigabatrin, neuroactive steroid Org 20599 and GABAB agonist 
R-baclofen on the SWD activity were investigated in WAG/Rij rats. These studies 
showed that these drugs differ in their effects on several properties of the SWDs, and 
that GABAA and GABAB mediated neurotransmission indeed differentially affect the 
properties of the SWDs. In chapter 5, the effects of vigabatrin on (“normal” type I) 
SWDs in WAG/Rij rats were investigated. This study showed that vigabatrin not only 
increases SWD activity, but also affects the peak frequency of these SWDs, as was 
shown in the previous chapters. Besides these quantitative effects vigabatrin affected 
the SWD stopping mechanism, as reﬂected by hazard rates, in a qualitative way. 
Furthermore, the time course of these effects corresponds to the reported time course 
of the effects on GABA concentrations (Hammond and Wilder, 1985; Valdizán et al., 
1999) and with the time course of the effects on type II SWDs (see chapter 2).
 Based on the previous chapters, it might be concluded that GABAA and GABAB 
mediated neurotransmission differentially affect the properties of the SWDs and thus 
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have a differential role in the mechanisms underlying the SWDs. Furthermore, it was 
shown that systemically administered vigabatrin, a drug affecting both GABAA and 
GABAB mediated neurotransmission, has pronounced effects on the SWDs, such 
as a decrease of the peak frequency of the SWDs. Then the question, from which 
parts of the thalamocortical network the effects of vigabatrin originate, arose.  In 
order to answer this last question, in chapter 6 the effects of vigabatrin on SWDs in 
WAG/Rij rats were simulated in a computational model. This study showed that the 
effects of vigabatrin on SWD activity can be reproduced best by a relative increase 
in GABAergic neurotransmission at the level of the thalamic relay nucleus (TC cells). 
Furthermore, since vigabatrin was shown to affect the hazard rate of SWD durations, it 
might be assumed that GABAergic neurotransmission in TC cells is actively involved in 
the process of absence seizure termination.
 Then, the question remained whether the GABAergic neurotransmission is 
either quantitatively or qualitatively (or both) involved in the mechanisms underlying 
the starting and stopping of the SWDs, and whether GABAA and GABAB mediated 
neurotransmission are differentially involved in these mechanisms. To answer this 
question, in chapter 7 the effects of several GABAergic drugs on the SWD activity in 
WAG/Rij rats were investigated. This study showed that in control rats the probability 
of a SWD starting decreases as the time since the last SWD increases, and that the 
probability of a SWD stopping increases the longer the SWD lasts. This study also 
showed that the benzodiazepine diazepam and GABAA agonist loreclezole (β2 and β3 
subunits) have anti-absence effects, and these effects are reﬂected in the effects on 
the hazard rates of the SWD durations and inter SWD durations. Neuroactive steroid 
Org 20599 was shown to have pro-absence effects, and the effects on the hazard 
rates show that after Org 20599 the probability of a SWD stopping increases the longer 
the SWD lasts and the probability of a SWD starting decreases as the time since the 
last SWD increases. Also, after Org 20599 the overall probability of a SWD starting 
is increased and the overall probability of a SWD stopping is decreased. This study 
also showed that after vigabatrin, GABAB agonist R-baclofen and GABAA agonist 
etomidate (β2 and β3 subunits), the SWD activity was increased. After these drugs, not 
only the overall probabilities of a SWD starting or stopping were affected, but also the 
course of the hazard rates was shown to be affected.
 To summarise, manipulation of different types of GABA receptors was shown 
to differentially affect the SWD activity. Systemic administration of GABA agonistic 
drugs resulted in an enhancement of SWD activity, with the exception of diazepam 
and loreclezole (discussed in 8.1.3.). It has been predicted that (relatively) enhancing 
GABAB-related neurotransmission in TC cells should slow down the peak frequency 
of SWDs (Destexhe, 1999; Destexhe and Sejnowski, 2003), which was conﬁrmed in 
this thesis (chapter 4). Also, it was shown that hazard rate analysis can be a useful tool 
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for hypothesising about the SWD starting and stopping mechanisms. Moreover, it was 
shown that this type of analysis might reveal more information on these mechanisms 
than the standard analysis of averages (of incidence and duration). In general, 
stimulation of GABAA receptors was shown to increase the probability of the generation 
of SWDs and to decrease the probability of the cessation of SWDs. Stimulation of 
GABAB receptors was also shown to increase the probability of SWD generation. 
Moreover, GABAB receptor activation not only decreased the probability of the 
stopping of a SWD, but also changed the course of this probability as the SWD lasts. 
Possible biological mechanisms responsible for these effects were discussed, and 
some possible types of drugs for the treatment of absence epilepsy were proposed.
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 In hoofdstuk 1 is eerst het begrip absence epilepsie geintroduceerd en 
uitgelegd. Daarnaast is ook het biologische circuit; waarvan gedacht wordt dat deze 
een rol spelt bij absence epilepsie, en het GABAerge neurotransmissie systeem 
uitgelegd. Vervolgens zijn de werkingsmechanismen van diverse GABAerge middelen 
en de variabelen die gemeten kunnen worden om de effecten van dergelijke middelen 
te beschrijven, geintroduceerd. Ook is de zogenaamde hazard rate analyse uitgelegd, 
aangezien deze analyse in dit proefschrift gebruikt is om de rol van GABA in de 
onderliggende mechanismen van absence epilepsie te onderzoeken.
Het doel van dit proefschrift:
 
Het doel was om de rol van het GABAerge neurotransmissie systeem in de 
onderliggende mechanismen van absence epilepsie verder te onderzoeken. 
Speciﬁeker, het doel van dit proefschrift was om te onderzoeken of de rol van 
GABAerge neurotransmissie in de onderliggende mechanismen van de absence 
epileptische piekgolf ontladingen (de SWDs) kwantitatief of kwalitatief (of beide) 
van aard is, en of die rol speciﬁek gedetermineerd wordt door GABAA of GABAB 
gemedieerde neurotransmissie.
 Om de effect van GABAerge neurotransmissie in zijn algemeen (zowel GABAA 
als GABAB gemedieerde neurotransmissie) op de eigenschappen van de type II SWDs 
te onderzoeken, zijn de effecten van de GABA transaminase inhibitor vigabatrine 
op type II SWDs in ACI ratten onderzocht in hoofdstuk 2. Deze studie liet zien dat 
vigabatrine niet alleen de type II SWD activiteit verhoogd, maar ook de piek frequentie 
van de type II SWDs beinvloed, zoals dat ook het geval was voor de “normale” 
type I SWDs (hoofdstukken 3, 4 en 5). Tevens werd in deze studie gedemonstreerd 
dat deze eigenschappen van de SWDs tijdsafhankelijk beinvloed werden door 
vigabatrine. In hoofdstukken 3 en 4, beoogd te determineren of GABAA en GABAB 
gemedieerde neurotransmissie een differentieele rol spelen in de bepaling van de 
verschillende eigenschappen van de SWDs, werden de effecten van vigabatrine, de 
neuroactieve steroid Org 20599 en GABAB agonist R-baclofen op de SWD activiteit 
onderzocht in WAG/Rij ratten. Deze studies lieten zien dat deze middelen verschillen 
in hun effecten op de verschillende eigenschappen van de SWDs, en dat  GABAA 
en GABAB gemedieerde neurotransmissie inderdaad de eigenschappen van de 
SWDs verschillend beinvloeden. In hoofdstuk 5, zijn de effecten van vigabatrine 
op (“normale” type I) SWDs in WAG/Rij ratten onderzocht. Deze studie liet zien dat 
vigabatrine niet alleen de SWD activiteit verhoogd, maar ook de piek frequentie van 
deze SWDs beinvloed, zoals ook te zien was in de eerdere hoofdstukken. Naast 
deze kwantitatieve effecten, beinvloede vigabatrine het stop mechanisme van de 
SWDs, zoals bepaald door middel van hazard rates, op een kwalitatieve wijze. Het 
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tijdsverloop van deze effecten komt overeen met het tijdsverloop van de effecten op 
GABA concentraties (Hammond and Wilder, 1985; Valdizán et al., 1999) en met het 
tijdsverloop van de effecten op type II SWDs (zie hoofdstuk 2).
 Op basis van de voorgaande hoofdstukken mag geconcludeerd worden dat 
GABAA en GABAB gemedieerde neurotransmissie de eigenschappen van de SWDs 
verschillend beinvloeden en dus een verschillende rol hebben in de onderliggende 
mechanismen van de de SWDs. Tevens is aangetoont dat het systemisch toedienen 
van vigabatrine, een drug die zowel GABAA als GABAB gemedieerde neurotransmissie 
beinvloed, duidelijke effecten op de SWDs heeft, zoals een daling van de piek 
frequentie van de SWDs. Dit leidde tot de vraag: welk deel van het thalamocorticale 
netwerk is verantwoordelijk voor de effecten van vigabatrine. Om deze vraag te 
kunnen beantwoorden zijn in hoofdstuk 6 de effecten van vigabatrine op SWDs 
in WAG/Rij ratten gesimuleerd in een computer model. Deze studie liet zien dat de 
effecten van vigabatrine op SWD activiteit het beste gereproduceerd kan worden 
door een relatieve verhoging in GABAerge neurotransmissie op het nivo van de 
thalamische relay nucleus (de TC cellen). Aangezien vigabatrine de hazard rate van de 
SWD duur beinvloed, mag aangenomen worden dat de GABAerge neurotransmissie 
in TC cellen actief betrokken is bij het stop-proces van de absence aanval.
 Dan rest nog de vraag of de GABAerge neurotransmissie kwantitatief of 
kwalitatief (of beide) betrokken is in de onderliggende mechanismen van het starten 
en stoppen van de SWDs en of  GABAA en GABAB gemedieerde neurotransmissie 
verschillen in hun betrokkenheid bij deze mechanismen. Om deze vraag te kunnen 
beantwoorden zijn in hoofdstuk 7 de effecten van diverse GABAerge middelen op de 
SWD activiteit in WAG/Rij ratten onderzocht. Deze studie liet zien dat in controle ratten 
de kans dat een SWD start daalt als de tijd sinds de vorige SWD stijgt, en dat de kans 
dat een SWD stopt stijgt  naarmate de SWD langer duurt. Deze studie liet ook zien 
dat de benzodiazepine diazepam en GABAA agonist loreclezole (β2 en β3 subunits) 
anti-absence effecten hebben, en dat deze effecten weerspiegelen in de effecten op 
de hazard rates van de SWD duur en inter SWD duur. De neuroactieve steroid Org 
20599  had een pro-absence effect, en de effecten op de hazard rates laten zien dat 
na Org 20599 de kans dat een SWD stopt stijgt naarmate de SWD langer duurt en dat 
de kans dat een SWD start daalt naarmate de tijd sinds de laatste SWD langer wordt. 
Tevens, na Org 20599 is de overall kans dat een  SWD start verhoogd en is de overall 
kans dat een SWD stopt verlaagd. Deze studie liet ook zien dat na vigabatrine, GABAB 
agonist R-baclofen en GABAA agonist etomidate (β2 en β3 subunits), de SWD activiteit 
verhoogd was. Na deze middelen waren niet alleen de overall kansen van het starten 
of stopen van een SWD beinvloed, maar ook het verloop van de hazard rates was 
veranderd.
 Samenvattend, manipulatie van verschillende typen GABA receptoren leidt tot 
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een verschil in beinvloeding van de SWD activiteit. Systemische toediening van GABA 
agonisten resulteerd in een verhoging van de SWD activiteit met als uitzonderingen 
diazepam en loreclezole (bediscussieerd in 8.1.3.). Er is voorspeld dat het (relatief) 
verhogen van de GABAB-gerelateerde neurotransmissie in TC cellen de piek 
frequentie van de SWDs zou verlagen (Destexhe, 1999; Destexhe and Sejnowski, 
2003), dit werd bevestigd in dit proefschrift (hoofdstuk 4). Ook is aangetoond dat 
analyse van hazard rates een waardevolle bijdrage kan leveren aan het onderzoeken 
van de SWD start- en stopmechanismen. Tevens is aangetoond dat deze analyse 
meer informatie over de mechanismen kan onthullen dan de standaard analyse van 
gemiddelden (van de incidentie en duur). Het stimuleren van GABAA receptoren 
resulteerd in het algemeen in een stijging in de kans dat een SWDs start en in een 
daling van de kans dat de SWD stopt. Stimulatie van GABAB receptoren leidt in het 
algemeen tot een stijging in de kans dat een SWD start. GABAB receptor activatie 
leidt niet alleen tot een daling van de kans date en SWD stopt, maar leidt zelfs tot een 
verandering in het verloop van deze kans naarmate de SWD langer duurt. Mogelijke 
biologische mechanismen die verantwoordelijk zouden kunnen zijn voor deze effecten 
warden bediscussieerd en mogelijke typen drugs voor de behandeling van absence 
epilesie werden genoemd. 
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 Dankwoord
 Na diverse pagina’s gevuld te hebben met wetenschappelijke taal wil ik nu 
proberen om in gewoon nederlands de mensen te bedanken die dit proefschrift 
mogelijk hebben gemaakt.
 Tineke, zonder jouw grenzeloos vertrouwen in mijn “artefacten” was dit alles 
nooit gelukt. Zelfs wanneer de materie echt te gecompliceerd dreigde te worden zijn 
wij er dankzij jouw “sesamstraat-logica” toch uit gekomen. Bedankt!
   Ton, jou wil ik vooral bedanken voor alle mogelijkheden die ik gekregen heb 
om mijn promotie-onderzoek te kunnen doen, en toch ook zo af en toe een beetje van 
het pad af te wijken. 
 De leden van de manuscriptcommissie, Gilles van Luijtelaar, Willy Renier en 
Giel Hekster wil ik bedanken voor het doorwerken van dit proefschrift. 
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